

CPC COOPERATIVE PATENT CLASSIFICATION

C CHEMISTRY; METALLURGY

(NOTES omitted)

CHEMISTRY

C12 BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING

(NOTES omitted)

C12N MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ([microbiological testing media C12Q 1/00](#))

NOTES

1. Attention is drawn to Notes (1) to (3) following the title of class [C12](#).
2. Biocidal, pest repellent, pest attractant or plant growth regulatory activity of compounds or preparations is further classified in subclass [A01P](#).
3. Therapeutic activity of single-cell proteins or enzymes is further classified in subclass [A61P](#).
4. When classifying in this subclass, classification is also made in group [B01D 15/08](#) insofar as subject matter of general interest relating to chromatography is concerned.
5. In this subclass, it is desirable to add the indexing codes of subclass [C12R](#).
6. {Documents relating to the use of vectors or hosts for the preparation of specific peptides, e.g. enzymes, are classified in subclass [C07K](#) or in group [C12N 9/00](#) according to the peptides, with the appropriate indexing codes.}
7. {In this subclass, combination sets [C-Sets] are used. The detailed information about the C-Sets construction and the associated syntax rules is present in the definitions of [C12N](#).}

WARNINGS

1. The following IPC groups are not in the CPC scheme. The subject matter for these IPC groups is classified in the following CPC groups:

| | | |
|--|------------|--|
| C12N 1/11 | covered by | C12N 15/79 |
| C12N 1/13 | covered by | C12N 15/79 |
| C12N 1/15 | covered by | C12N 15/80 |
| C12N 1/19 | covered by | C12N 15/81 |
| C12N 1/21 | covered by | C12N 15/74 |
| C12N 5/02 | covered by | C12N 5/0006 , C12N 5/04 - C12N 5/166 |
| C12N 5/07 - C12N 5/095 | covered by | C12N 5/06 |
| C12N 5/18 | covered by | C12N 5/16 |
| C12N 5/20 | covered by | C12N 5/163 |
| C12N 5/22 | covered by | C12N 5/16 |
| C12N 5/24 | covered by | C12N 5/163 |
| C12N 5/26 | covered by | C12N 5/166 |
| C12N 5/28 | covered by | C12N 5/166 |
| C12N 15/53 | covered by | C12N 9/0004 |
| C12N 7/01 | covered by | C12N 7/00 |
| C12N 9/02 - C12N 9/08 | covered by | C12N 9/0004 |
| C12N 9/26 | covered by | C12N 9/2408 |
| C12N 9/28 - C12N 9/30 | covered by | C12N 9/2414 - C12N 9/242 |
| C12N 9/32 | covered by | C12N 9/2422 |
| C12N 9/34 | covered by | C12N 9/2428 |
| C12N 9/36 | covered by | C12N 9/2462 |
| C12N 9/38 | covered by | C12N 9/2468 |
| C12N 9/40 | covered by | C12N 9/2465 |
| C12N 9/42 | covered by | C12N 9/2434 |
| C12N 9/44 | covered by | C12N 9/2451 |
| C12N 9/46 | covered by | C12N 9/2454 |
| C12N 9/56 | covered by | C12N 9/54 |
| C12N 9/66 | covered by | C12N 9/6448 |
| C12N 9/68 | covered by | C12N 9/6435 |
| C12N 9/70 | covered by | C07K 14/3153 |
| C12N 9/72 | covered by | C12N 9/6462 |

C12N

C12N
(continued)

| | | |
|------------|------------|--|
| C12N 9/74 | covered by | C12N 9/6429 |
| C12N 9/76 | covered by | C12N 9/6427 |
| C12N 15/05 | covered by | C12N 5/14 |
| C12N 15/06 | covered by | C12N 5/16 |
| C12N 15/07 | covered by | C12N 5/16 |
| C12N 15/08 | covered by | C12N 5/166 |
| C12N 15/12 | covered by | C07K 14/435 |
| C12N 15/13 | covered by | C07K 16/00 |
| C12N 15/14 | covered by | C07K 14/765 |
| C12N 15/15 | covered by | C07K 14/81 |
| C12N 15/16 | covered by | C07K 14/575 |
| C12N 15/17 | covered by | C07K 14/62 |
| C12N 15/18 | covered by | C07K 14/61 |
| C12N 15/19 | covered by | C07K 14/52 |
| C12N 15/20 | covered by | C07K 14/555 |
| C12N 15/21 | covered by | C07K 14/56 |
| C12N 15/22 | covered by | C07K 14/565 |
| C12N 15/23 | covered by | C07K 14/57 |
| C12N 15/24 | covered by | C07K 14/54 |
| C12N 15/25 | covered by | C07K 14/545 |
| C12N 15/26 | covered by | C07K 14/55 |
| C12N 15/27 | covered by | C07K 14/53 |
| C12N 15/28 | covered by | C07K 14/525 |
| C12N 15/29 | covered by | C07K 14/415 |
| C12N 15/30 | covered by | C07K 14/44 |
| C12N 15/31 | covered by | C07K 14/195 , C07K 14/005 |
| C12N 15/32 | covered by | C07K 14/325 |
| C12N 15/33 | covered by | C07K 14/005 |
| C12N 15/34 | covered by | C07K 14/01 |
| C12N 15/35 | covered by | C07K 14/015 |
| C12N 15/36 | covered by | C07K 14/02 |
| C12N 15/37 | covered by | C07K 14/025 |
| C12N 15/38 | covered by | C07K 14/03 |
| C12N 15/39 | covered by | C07K 14/065 |
| C12N 15/40 | covered by | C07K 14/08 |
| C12N 15/41 | covered by | C07K 14/085 |
| C12N 15/42 | covered by | C07K 14/09 |
| C12N 15/43 | covered by | C07K 14/105 |
| C12N 15/44 | covered by | C07K 14/11 |
| C12N 15/45 | covered by | C07K 14/115 |
| C12N 15/46 | covered by | C07K 14/14 |
| C12N 15/47 | covered by | C07K 14/145 |
| C12N 15/48 | covered by | C07K 14/15 |
| C12N 15/49 | covered by | C07K 14/155 |
| C12N 15/50 | covered by | C07K 14/165 |
| C12N 15/51 | covered by | C07K 14/02 , C07K 14/10 , C07K 14/18 |
| C12N 15/53 | covered by | C12N 9/0004 |
| C12N 15/54 | covered by | C12N 9/10 |
| C12N 15/55 | covered by | C12N 9/14 |
| C12N 15/56 | covered by | C12N 9/24 |
| C12N 15/57 | covered by | C12N 9/48 |
| C12N 15/58 | covered by | C12N 9/6456 |
| C12N 15/59 | covered by | C12N 9/6483 |
| C12N 15/60 | covered by | C12N 9/88 |
| C12N 15/61 | covered by | C12N 9/90 |
| C12N 15/83 | covered by | C12N 15/82 |
| C12N 15/84 | covered by | C12N 15/82 |

2. In this subclass non-limiting references (in the sense of paragraph 39 of the Guide to the IPC) may still be displayed in the scheme.

- 1/00 Microorganisms, e.g. protozoa; Compositions thereof** (medicinal preparations containing material from protozoa, bacteria or viruses [A61K 35/66](#), from algae [A61K 36/02](#), from fungi [A61K 36/06](#); preparing medicinal bacterial antigen or antibody compositions, e.g. bacterial vaccines, [A61K 39/00](#)); **Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor**
- 1/005 . {after treatment of microbial biomass not covered by [C12N 1/02](#) - [C12N 1/08](#)}
- 1/02 . Separating microorganisms from their culture media
- 1/04 . Preserving or maintaining viable microorganisms (immobilised microorganisms [C12N 11/00](#))
- 1/06 . Lysis of microorganisms
- 1/063 . . {of yeast}
- 1/066 . . {by physical methods}
- 1/08 . Reducing the nucleic acid content
- 1/10 . Protozoa; Culture media therefor
- 1/105 . . {Protozoal isolates}
- 1/12 . Unicellular algae; Culture media therefor (as new plants [A01H 13/00](#))
- 1/125 . . {Unicellular algae isolates}
- 1/14 . Fungi (culture of mushrooms [A01G 18/00](#); as new plants [A01H 15/00](#)); Culture media therefor
- 1/145 . . {Fungal isolates}
- 1/16 . . Yeasts; Culture media therefor
- 1/165 . . . {Yeast isolates}
- 1/18 . . . Baker's yeast; Brewer's yeast
- 1/185 {Saccharomyces isolates}
- 1/20 . Bacteria; Culture media therefor
- 1/205 . . {Bacterial isolates}
- 1/22 . Processes using, or culture media containing, cellulose or hydrolysates thereof
- 1/24 . Processes using, or culture media containing, waste sulfite liquor
- 1/26 . Processes using, or culture media containing, hydrocarbons (refining of hydrocarbon oils by using microorganisms [C10G 32/00](#))
- 1/28 . . aliphatic
- 1/30 . . . having five or less carbon atoms
- 1/32 . Processes using, or culture media containing, lower alkanols, i.e. C₁ to C₆
- 1/34 . Processes using foam culture
- 1/36 . Adaptation or attenuation of cells
- 1/38 . Chemical stimulation of growth or activity by addition of chemical compounds which are not essential growth factors; Stimulation of growth by removal of a chemical compound ([C12N 1/34](#) takes precedence)
- 3/00 Spore forming or isolating processes**
- 5/00 Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor;** (plant reproduction by tissue culture techniques [A01H 4/00](#))
- NOTE**
- In this group, the following words are used with the meanings indicated:
- a "totipotent" cell can differentiate into all somatic lineages (ectoderm, mesoderm, endoderm), the germ line and extra-embryonic tissues such as the placenta;
 - a "pluripotent" cell is a somatic stem cell which can differentiate into cells of at least two of the three somatic lineages (ectoderm, mesoderm, endoderm);
 - a "multipotent" cell is restricted to one lineage. }
- "Progenitor" and "precursor" cells are further restricted within the lineage. If not explicitly foreseen, totipotent cells are classified with pluripotent cells. Multipotent cells should not be classified with pluripotent cells. Unless provided for otherwise, committed progenitors are classified with their progeny.
- 5/0006 . {Modification of the membrane of cells, e.g. cell decoration}
- 5/0012 . {Cell encapsulation}
- 5/0018 . {Culture media for cell or tissue culture (media for specific animal cell type [C12N 5/06](#))}
- 5/0025 . . {Culture media for plant cell or plant tissue culture}
- 5/0031 . . {Serum-free culture media}
- WARNING**
- This group is no longer used for the classification of new documents as from January 1, 2012. The backlog of this group is being continuously reclassified to [C12N 5/0037](#) - [C12N 5/0056](#)
- 5/0037 . . {Serum-free medium, which may still contain naturally-sourced components}
- 5/0043 . . {Medium free of human- or animal-derived components}
- 5/005 . . {Protein-free medium}
- 5/0056 . . {Xeno-free medium}
- 5/0062 . {General methods for three-dimensional culture}
- 5/0068 . {General culture methods using substrates (for specific animal cell type [C12N 5/06](#))}
- 5/0075 . . {using microcarriers}
- 5/0081 . {Purging biological preparations of unwanted cells}
- 5/0087 . . {Purging against subsets of blood cells, e.g. purging alloreactive T cells}
- 5/0093 . . {Purging against cancer cells}
- 5/04 . Plant cells or tissues {(culture media [C12N 5/0025](#))}
- 5/06 . {Animal cells or tissues; Human cells or tissues (preservation of living cells or tissues [A01N 1/02](#))}
- NOTE**
- {In this group, the following words are used with the meanings indicated:
- a "totipotent" cell can differentiate into all somatic lineages (ectoderm, mesoderm, endoderm), the germ line and extra-embryonic tissues such as the placenta;
 - a "pluripotent" cell is a somatic stem cell which can differentiate into cells of at least two of the three somatic lineages (ectoderm, mesoderm, endoderm);
 - a "multipotent" cell is restricted to one lineage. }
- "Progenitor" and "precursor" cells are further restricted within the lineage. If not explicitly foreseen, totipotent cells are classified with

C12N

C12N 5/06
(continued)

pluripotent cells. Multipotent cells should not be classified with pluripotent cells. The last place priority rule does not apply between the subgroups of this group

- 5/0601 . . {Invertebrate cells or tissues, e.g. insect cells; Culture media therefor}
- 5/0602 . . {Vertebrate cells}

NOTE

Three-dimensional culture, tissue culture or organ culture are classified with the corresponding cells, if not specially provided for

- 5/0603 . . . {Embryonic cells (production of embryos, nuclear transfer [A01K 67/027](#)); Embryoid bodies}
- 5/0604 {Whole embryos; Culture medium therefor}
- 5/0605 {Cells from extra-embryonic tissues, e.g. placenta, amnion, yolk sac, Wharton's jelly}
- 5/0606 {Pluripotent embryonic cells, e.g. embryonic stem cells [ES] (embryonic germ cells [C12N 5/0611](#), induced pluripotent stem cells [C12N 5/0696](#))}
- 5/0607 . . . {Non-embryonic pluripotent stem cells, e.g. MASC (induced pluripotent stem cells [C12N 5/0696](#))}
- 5/0608 . . . {Germ cells (production of embryos, nuclear transfer [A01K 67/027](#))}
- 5/0609 {Oocytes, oogonia (fertilised oocytes [C12N 5/0604](#))}
- 5/061 {Sperm cells, spermatogonia}
- 5/0611 {Primordial germ cells, e.g. embryonic germ cells [EG]}
- 5/0612 {sorting of gametes, e.g. according to sex or motility}
- 5/0613 . . . {Cells from endocrine organs (pancreas [C12N 5/0676](#), gonads [C12N 5/0681](#))}
- 5/0614 {Adrenal gland}
- 5/0615 {Pineal gland}
- 5/0616 {Pituitary gland}
- 5/0617 {Thyroid and parathyroid glands}
- 5/0618 . . . {Cells of the nervous system}
- 5/0619 {Neurons}
- 5/062 {Sensory transducers, e.g. photoreceptors; Sensory neurons, e.g. for hearing, taste, smell, pH, touch, temperature, pain}
- 5/0621 {Eye cells, e.g. cornea, iris pigmented cells (photoreceptors [C12N 5/062](#))}
- 5/0622 {Glial cells, e.g. astrocytes, oligodendrocytes; Schwann cells}
- 5/0623 {Stem cells}
- 5/0625 . . . {Epidermal cells, skin cells; Cells of the oral mucosa}
- 5/0626 {Melanocytes}
- 5/0627 {Hair cells}
- 5/0628 {Hair stem cells; Hair progenitors (mesenchymal stem cells from hair follicles [C12N 5/0666](#))}
- 5/0629 {Keratinocytes; Whole skin}
- 5/063 {Keratinocyte stem cells; Keratinocyte progenitors}
- 5/0631 {Mammary cells}
- 5/0632 {Cells of the oral mucosa}

- 5/0633 {Cells of secretory glands, e.g. parotid gland, salivary glands, sweat glands, lacrymal glands}
- 5/0634 . . . {Cells from the blood or the immune system}

NOTE

Committed progenitors are classified with their progeny

WARNING

Group [C12N 5/0634](#) is impacted by reclassification into groups [A61K 39/46](#), [A61K 39/461](#) - [A61K 39/46484](#) and [A61K 2239/00](#) - [A61K 2239/59](#).

All groups listed in this Warning should be considered in order to perform a complete search.

- 5/0635 {B lymphocytes}

WARNING

Group [C12N 5/0635](#) is impacted by reclassification into groups [A61K 39/46](#), [A61K 39/461](#) - [A61K 39/46484](#) and [A61K 2239/00](#) - [A61K 2239/59](#).

All groups listed in this Warning should be considered in order to perform a complete search.

- 5/0636 {T lymphocytes}

WARNING

Group [C12N 5/0636](#) is impacted by reclassification into groups [A61K 39/46](#), [A61K 39/461](#) - [A61K 39/46484](#) and [A61K 2239/00](#) - [A61K 2239/59](#).

All groups listed in this Warning should be considered in order to perform a complete search.

- 5/0637 {Immunosuppressive T lymphocytes, e.g. regulatory T cells or Treg}

WARNING

Group [C12N 5/0637](#) is impacted by reclassification into groups [A61K 39/46](#), [A61K 39/461](#) - [A61K 39/46484](#) and [A61K 2239/00](#) - [A61K 2239/59](#).

All groups listed in this Warning should be considered in order to perform a complete search.

- 5/0638 {Cytotoxic T lymphocytes [CTL] or lymphokine activated killer cells [LAK]}

WARNING

Group [C12N 5/0638](#) is impacted by reclassification into groups [A61K 39/46](#), [A61K 39/461](#) - [A61K 39/46484](#) and [A61K 2239/00](#) - [A61K 2239/59](#).

All groups listed in this Warning should be considered in order to perform a complete search.

| | | | |
|--------|--|--------|--|
| 5/0639 | {Dendritic cells, e.g. Langerhans cells in the epidermis} | 5/0658 | {Skeletal muscle cells, e.g. myocytes, myotubes, myoblasts} |
| | WARNING | 5/0659 | {Satellite cells} |
| | Group C12N 5/0639 is impacted by reclassification into groups A61K 39/46 , A61K 39/461 - A61K 39/46484 and A61K 2239/00 - A61K 2239/59 . | 5/066 | {Tenocytes; Tendons, Ligaments} |
| | All groups listed in this Warning should be considered in order to perform a complete search. | 5/0661 | {Smooth muscle cells} |
| 5/064 | {Immunosuppressive dendritic cells} | 5/0662 | {Stem cells} |
| | WARNING | 5/0663 | {Bone marrow mesenchymal stem cells (BM-MSC)} |
| | Group C12N 5/064 is impacted by reclassification into groups A61K 39/46 , A61K 39/461 - A61K 39/46484 and A61K 2239/00 - A61K 2239/59 . | 5/0664 | {Dental pulp stem cells, Dental follicle stem cells} |
| | All groups listed in this Warning should be considered in order to perform a complete search. | 5/0665 | {Blood-borne mesenchymal stem cells, e.g. from umbilical cord blood} |
| 5/0641 | {Erythrocytes} | 5/0666 | {Mesenchymal stem cells from hair follicles} |
| 5/0642 | {Granulocytes, e.g. basophils, eosinophils, neutrophils, mast cells} | 5/0667 | {Adipose-derived stem cells [ADSC]; Adipose stromal stem cells} |
| 5/0643 | {Osteoclasts} | 5/0668 | {Mesenchymal stem cells from other natural sources} |
| 5/0644 | {Platelets; Megakaryocytes} | 5/0669 | {Bone marrow stromal cells; Whole bone marrow (isolated stem cells from bone marrow C12N 5/0647 , C12N 5/0663)} |
| 5/0645 | {Macrophages, e.g. Kuepfer cells in the liver; Monocytes} | 5/067 | . . . {Hepatocytes} |
| | WARNING | 5/0671 | {Three-dimensional culture, tissue culture or organ culture; Encapsulated cells} |
| | Group C12N 5/0645 is impacted by reclassification into groups A61K 39/46 , A61K 39/461 - A61K 39/46484 and A61K 2239/00 - A61K 2239/59 . | 5/0672 | {Stem cells; Progenitor cells; Precursor cells; Oval cells} |
| | All groups listed in this Warning should be considered in order to perform a complete search. | 5/0676 | . . . {Pancreatic cells} |
| 5/0646 | {Natural killers cells [NK], NKT cells} | 5/0677 | {Three-dimensional culture, tissue culture or organ culture; Encapsulated cells} |
| | WARNING | 5/0678 | {Stem cells; Progenitor cells; Precursor cells} |
| | Group C12N 5/0646 is impacted by reclassification into groups A61K 39/46 , A61K 39/461 - A61K 39/46484 , A61K 2239/00 - A61K 2239/59 . | 5/0679 | . . . {Cells of the gastro-intestinal tract} |
| | All groups listed in this Warning should be considered in order to perform a complete search. | 5/068 | {Stem cells; Progenitors} |
| 5/0647 | {Haematopoietic stem cells; Uncommitted or multipotent progenitors} | 5/0681 | . . . {Cells of the genital tract; Non-germinal cells from gonads} |
| 5/0648 | {Splenocytes} | 5/0682 | {Cells of the female genital tract, e.g. endometrium; Non-germinal cells from ovaries, e.g. ovarian follicle cells (oocytes C12N 5/0609)} |
| 5/065 | {Thymocytes} | 5/0683 | {Cells of the male genital tract, e.g. prostate, epididymis; Non-germinal cells from testis, e.g. Leydig cells, Sertoli cells (spermatogonia C12N 5/061)} |
| 5/0651 | {Lymph nodes} | 5/0684 | . . . {Cells of the urinary tract or kidneys} |
| 5/0652 | . . . {Cells of skeletal and connective tissues; Mesenchyme} | 5/0685 | {Bladder epithelial cells} |
| 5/0653 | {Adipocytes; Adipose tissue} | 5/0686 | {Kidney cells} |
| 5/0654 | {Osteocytes, Osteoblasts, Odontocytes; Bones, Teeth} | 5/0687 | {Renal stem cells; Renal progenitors} |
| 5/0655 | {Chondrocytes; Cartilage} | 5/0688 | . . . {Cells from the lungs or the respiratory tract} |
| 5/0656 | {Adult fibroblasts} | 5/0689 | {Stem cells; Progenitors} |
| 5/0657 | {Cardiomyocytes; Heart cells} | 5/069 | . . . {Vascular Endothelial cells} |
| | | 5/0691 | {Vascular smooth muscle cells; 3D culture thereof, e.g. models of blood vessels} |
| | | 5/0692 | {Stem cells; Progenitor cells; Precursor cells} |
| | | 5/0693 | . . . {Tumour cells; Cancer cells} |
| | | 5/0694 | {Cells of blood, e.g. leukemia cells, myeloma cells} |
| | | 5/0695 | {Stem cells; Progenitor cells; Precursor cells} |
| | | 5/0696 | . . . {Artificially induced pluripotent stem cells, e.g. iPS} |
| | | 5/0697 | . . {Artificial constructs associating cells of different lineages, e.g. tissue equivalents (blood vessels C12N 5/0691)} |

- 5/0698 . . . {Skin equivalents}
- 5/10 . Cells modified by introduction of foreign genetic material
- 5/12 . . Fused cells, e.g. hybridomas
- 5/14 . . . Plant cells
- 5/16 . . . Animal cells
- 5/163 {one of the fusion partners being a B or a T lymphocyte}
- 5/166 {resulting from interspecies fusion}
- 7/00 Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof (preparing medicinal viral antigen or antibody compositions, e.g. virus vaccines, [A61K 39/00](#))**
- WARNING**
- From March 15, 2012 groups [C12N 7/02](#) - [C12N 7/08](#) and subgroups thereof are no longer used for the classification of new documents. The documents in these (sub)groups are being reclassified to the corresponding codes in the range [C12N 2710/00-C12N 2795/00](#).
- 7/02 . Recovery or purification
- 7/025 . . {Packaging cell lines, e.g. transcomplementing cell lines, for production of virus}
- 7/04 . Inactivation or attenuation; Producing viral sub-units
- 7/045 . . {Pseudoviral particles; Non infectious pseudovirions, e.g. genetically engineered}
- 7/06 . . {Inactivation or attenuation} by chemical treatment
- 7/08 . . {Inactivation or attenuation} by serial passage of virus
- 9/00 Enzymes; Proenzymes; Compositions thereof (preparations containing enzymes for cleaning teeth [A61K 8/66](#), [A61Q 11/00](#); medicinal preparations containing enzymes or proenzymes [A61K 38/43](#); enzyme containing detergent compositions [C11D](#); {enzymes with nucleic acid structure, e.g. ribozymes, [C12N 15/113](#)}); Processes for preparing, activating, inhibiting, separating or purifying enzymes (preparation of malt [C12C 1/00](#))**
- NOTE**
- Enzymes are generally categorized below according to the "Nomenclature and Classification of Enzymes" of the International Commission on Enzymes. Where appropriate, this designation appears in the groups below in parenthesis.
- 9/0002 . {Antibodies with enzymatic activity, e.g. abzymes}
- 9/0004 . {Oxidoreductases (1.)}
- 9/0006 . . {acting on CH-OH groups as donors (1.1)}
- 9/0008 . . {acting on the aldehyde or oxo group of donors (1.2)}
- 9/001 . . {acting on the CH-CH group of donors (1.3)}
- 9/0012 . . {acting on nitrogen containing compounds as donors (1.4, 1.5, 1.6, 1.7)}
- 9/0014 . . . {acting on the CH-NH₂ group of donors (1.4)}
- 9/0016 {with NAD or NADP as acceptor (1.4.1)}
- 9/0018 {Phenylalanine dehydrogenase (1.4.1.20)}
- 9/002 {with a cytochrome as acceptor (1.4.2)}
- 9/0022 {with oxygen as acceptor (1.4.3)}
- 9/0024 {D-Amino acid oxidase (1.4.3.3)}
- 9/0026 . . . {acting on CH-NH groups of donors (1.5)}
- 9/0028 {with NAD or NADP as acceptor (1.5.1)}
- 9/003 {Dihydrofolate reductase [DHFR] (1.5.1.3)}
- 9/0032 {with oxygen as acceptor (1.5.3)}
- 9/0034 {Sarcosine oxidase (1.5.3.1)}
- 9/0036 . . . {acting on NADH or NADPH (1.6)}
- 9/0038 {with a heme protein as acceptor (1.6.2)}
- 9/004 {Cytochrome-b5 reductase (1.6.2.2)}
- 9/0042 {NADPH-cytochrome P450 reductase (1.6.2.4)}
- 9/0044 . . . {acting on other nitrogen compounds as donors (1.7)}
- 9/0046 {with oxygen as acceptor (1.7.3)}
- 9/0048 {Uricase (1.7.3.3)}
- 9/0051 . . {acting on a sulfur group of donors (1.8)}
- 9/0053 . . {acting on a heme group of donors (1.9)}
- 9/0055 . . {acting on diphenols and related substances as donors (1.10)}
- 9/0057 . . . {with oxygen as acceptor (1.10.3)}
- 9/0059 {Catechol oxidase (1.10.3.1), i.e. tyrosinase}
- 9/0061 {Laccase (1.10.3.2)}
- 9/0063 {Ascorbate oxidase (1.10.3.3)}
- 9/0065 . . {acting on hydrogen peroxide as acceptor (1.11)}
- 9/0067 . . {acting on hydrogen as donor (1.12)}
- 9/0069 . . {acting on single donors with incorporation of molecular oxygen, i.e. oxygenases (1.13)}
- 9/0071 . . {acting on paired donors with incorporation of molecular oxygen (1.14)}
- 9/0073 . . . {with NADH or NADPH as one donor, and incorporation of one atom of oxygen 1.14.13}
- 9/0075 {Nitric-oxide synthase (1.14.13.39)}
- 9/0077 . . . {with a reduced iron-sulfur protein as one donor (1.14.15)}
- 9/0079 {Steroid 11 beta monooxygenase (P-450 protein)(1.14.15.4)}
- 9/0081 {Cholesterol monooxygenase (cytochrome P 450sc)(1.14.15.6)}
- 9/0083 . . . {Miscellaneous (1.14.99)}
- 9/0085 {Steroid 17 alpha-monooxygenase (1.14.99.9)}
- 9/0087 {Steroid 21-monooxygenase (1.14.99.10)}
- 9/0089 . . {acting on superoxide as acceptor (1.15)}
- 9/0091 . . {oxidizing metal ions (1.16)}
- 9/0093 . . {acting on CH or CH₂ groups (1.17)}
- 9/0095 . . {acting on iron-sulfur proteins as donor (1.18)}
- 9/0097 . . {acting on reduced flavodoxin as donor (1.19)}
- 9/10 . Transferases (2.) (ribonucleases [C12N 9/22](#))
- 9/1003 . . {transferring one-carbon groups (2.1)}
- 9/1007 . . . {Methyltransferases (general) (2.1.1.)}
- 9/1011 {Catechol O-methyltransferase (2.1.1.6)}
- 9/1014 . . . {Hydroxymethyl-, formyl-transferases (2.1.2)}
- 9/1018 . . . {Carboxy- and carbamoyl transferases (2.1.3)}
- 9/1022 . . {transferring aldehyde or ketonic groups (2.2)}
- 9/1025 . . {Acyltransferases (2.3)}
- 9/1029 . . . {transferring groups other than amino-acyl groups (2.3.1)}
- 9/1033 {Chloramphenicol O-acetyltransferase (2.3.1.28)}
- 9/1037 {Naringenin-chalcone synthase (2.3.1.74), i.e. chalcone synthase}
- 9/104 . . . {Aminoacyltransferases (2.3.2)}

| | | | |
|--------|---|--------|---|
| 9/1044 | {Protein-glutamine gamma-glutamyltransferase (2.3.2.13), i.e. transglutaminase or factor XIII} | 9/2411 | {Amylases} |
| 9/1048 | . . {Glycosyltransferases (2.4)} | 9/2414 | {Alpha-amylase (3.2.1.1.)} |
| 9/1051 | . . . {Hexosyltransferases (2.4.1)} | 9/2417 | {from microbiological source} |
| 9/1055 | {Levansucrase (2.4.1.10)} | 9/242 | {Fungal source} |
| 9/1059 | {Cellulose synthases (2.4.1.12; 2.4.1.29)} | 9/2422 | {from plant source} |
| 9/1062 | {Sucrose synthase (2.4.1.13)} | 9/2425 | {Beta-amylase (3.2.1.2)} |
| 9/1066 | {Sucrose phosphate synthase (2.4.1.14)} | 9/2428 | {Glucan 1,4-alpha-glucosidase (3.2.1.3), i.e. glucoamylase} |
| 9/107 | {1,4-Alpha-glucan branching enzyme (2.4.1.18)} | 9/2431 | {Beta-fructofuranosidase (3.2.1.26), i.e. invertase} |
| 9/1074 | {Cyclomaltodextrin glucanotransferase (2.4.1.19)} | 9/2434 | {acting on beta-1,4-glucosidic bonds} |
| 9/1077 | . . . {Pentosyltransferases (2.4.2)} | 9/2437 | {Cellulases (3.2.1.4; 3.2.1.74; 3.2.1.91; 3.2.1.150)} |
| 9/1081 | . . . {transferring other glycosyl groups (2.4.99)} | 9/244 | {Endo-1,3(4)-beta-glucanase (3.2.1.6)} |
| 9/1085 | . . {transferring alkyl or aryl groups other than methyl groups (2.5)} | 9/2442 | {Chitinase (3.2.1.14)} |
| 9/1088 | . . . {Glutathione transferase (2.5.1.18)} | 9/2445 | {Beta-glucosidase (3.2.1.21)} |
| 9/1092 | . . . {3-Phosphoshikimate 1-carboxyvinyltransferase (2.5.1.19), i.e. 5-enolpyruvylshikimate-3-phosphate synthase} | 9/2448 | {Licheninase (3.2.1.73)} |
| 9/1096 | . . {transferring nitrogenous groups (2.6)} | 9/2451 | {acting on alpha-1,6-glucosidic bonds} |
| 9/12 | . . transferring phosphorus containing groups, e.g. kinases (2.7) | 9/2454 | {Dextranase (3.2.1.11)} |
| 9/1205 | . . . {Phosphotransferases with an alcohol group as acceptor (2.7.1), e.g. protein kinases} | 9/2457 | {Pullulanase (3.2.1.41)} |
| 9/1211 | {Thymidine kinase (2.7.1.21)} | 9/246 | {Isoamylase (3.2.1.68)} |
| 9/1217 | . . . {Phosphotransferases with a carboxyl group as acceptor (2.7.2)} | 9/2462 | {Lysozyme (3.2.1.17)} |
| 9/1223 | . . . {Phosphotransferases with a nitrogenous group as acceptor (2.7.3)} | 9/2465 | {acting on alpha-galactose-glycoside bonds, e.g. alpha-galactosidase (3.2.1.22)} |
| 9/1229 | . . . {Phosphotransferases with a phosphate group as acceptor (2.7.4)} | 9/2468 | {acting on beta-galactose-glycoside bonds, e.g. carrageenases (3.2.1.83; 3.2.1.157); beta-agarase (3.2.1.81)} |
| 9/1235 | . . . {Diphosphotransferases (2.7.6)} | 9/2471 | {Beta-galactosidase (3.2.1.23), i.e. exo-(1->4)-beta-D-galactanase} |
| 9/1241 | . . . {Nucleotidyltransferases (2.7.7)} | 9/2474 | {Hyaluronoglucosaminidase (3.2.1.35), i.e. hyaluronidase} |
| 9/1247 | {DNA-directed RNA polymerase (2.7.7.6)} | 9/2477 | {Hemicellulases not provided in a preceding group} |
| 9/1252 | {DNA-directed DNA polymerase (2.7.7.7), i.e. DNA replicase} | 9/248 | {Xylanases} |
| 9/1258 | {Polyribonucleotide nucleotidyltransferase (2.7.7.8), i.e. polynucleotide phosphorylase} | 9/2482 | {Endo-1,4-beta-xylanase (3.2.1.8)} |
| 9/1264 | {DNA nucleotidylexotransferase (2.7.7.31), i.e. terminal nucleotidyl transferase} | 9/2485 | {Xylan endo-1,3-beta-xylosidase (3.2.1.32), i.e. endo-1,3-beta-xylanase} |
| 9/127 | {RNA-directed RNA polymerase (2.7.7.48), i.e. RNA replicase} | 9/2488 | {Mannanases} |
| 9/1276 | {RNA-directed DNA polymerase (2.7.7.49), i.e. reverse transcriptase or telomerase} | 9/2491 | {Beta-mannosidase (3.2.1.25), i.e. mannanase} |
| 9/1282 | {RNA uridylyltransferase (2.7.7.52)} | 9/2494 | {Mannan endo-1,4-beta-mannosidase (3.2.1.78), i.e. endo-beta-mannanase} |
| 9/1288 | . . . {Transferases for other substituted phosphate groups (2.7.8)} | 9/2497 | . . . {hydrolysing N- glycosyl compounds (3.2.2)} |
| 9/1294 | . . . {Phosphotransferases with paired acceptors (2.7.9)} | 9/48 | . . acting on peptide bonds (3.4) |
| 9/13 | . . {transferring sulfur containing groups (2.8)} | 9/485 | . . . {Exopeptidases (3.4.11-3.4.19)} |
| 9/14 | . Hydrolases (3) | 9/50 | . . . Proteinases {, e.g. Endopeptidases (3.4.21-3.4.25)} |
| 9/16 | . . acting on ester bonds (3.1) | 9/503 | {derived from viruses} |
| 9/18 | . . . Carboxylic ester hydrolases {(3.1.1)} | 9/506 | {derived from RNA viruses} |
| 9/20 | Triglyceride splitting, e.g. by means of lipase | 9/52 | derived from bacteria {or Archaea} |
| 9/22 | . . . Ribonucleases {RNAses, DNAses (catalytic nucleic acids C12N 15/113)} | | NOTE |
| 9/24 | . . acting on glycosyl compounds (3.2) | | {In this group, Archaea, formerly known as Archaeobacteria, are classified with bacteria.} |
| 9/2402 | . . . {hydrolysing O- and S- glycosyl compounds (3.2.1)} | 9/54 | bacteria being Bacillus |
| 9/2405 | {Glucanases} | 9/58 | derived from fungi |
| 9/2408 | {acting on alpha -1,4-glucosidic bonds} | 9/60 | from yeast |
| | | 9/62 | from Aspergillus |
| | | 9/63 | {derived from plants} |
| | | 9/64 | derived from animal tissue |
| | | 9/6402 | {from non-mammals} |

- 9/6405 {not being snakes}
- 9/6408 {Serine endopeptidases (3.4.21)}
- 9/641 {Cysteine endopeptidases (3.4.22)}
- 9/6413 {Aspartic endopeptidases (3.4.23)}
- 9/6416 {Metalloendopeptidases (3.4.24)}
- 9/6418 {from snakes}
- 9/6421 {from mammals}
- 9/6424 {Serine endopeptidases (3.4.21)}
- 9/6427 {Chymotrypsins (3.4.21.1; 3.4.21.2);
Trypsin (3.4.21.4)}
- 9/6429 {Thrombin (3.4.21.5)}
- 9/6432 {Coagulation factor Xa (3.4.21.6)}
- 9/6435 {Plasmin (3.4.21.7), i.e. fibrinolysin}
- 9/6437 {Coagulation factor VIIa (3.4.21.21)}
- 9/644 {Coagulation factor IXa (3.4.21.22)}
- 9/6443 {Coagulation factor XIa (3.4.21.27)}
- 9/6445 {Kallikreins (3.4.21.34; 3.4.21.35)}
- 9/6448 {Elastases, e.g. pancreatic elastase
(3.4.21.36); leukocyte elastase
(3.4.31.37)}
- 9/6451 {Coagulation factor XIIa (3.4.21.38)}
- 9/6454 {Dibasic site splicing serine
proteases, e.g. kexin (3.4.21.61);
furin (3.4.21.75) and other proprotein
convertases}
- 9/6456 {Plasminogen activators}
- 9/6459 {t-plasminogen activator
(3.4.21.68), i.e. tPA}
- 9/6462 {u-Plasminogen activator
(3.4.21.73), i.e. urokinase}
- 9/6464 {Protein C (3.4.21.69)}
- 9/6467 {Granzymes, e.g. granzyme A
(3.4.21.78); granzyme B (3.4.21.79)}
- 9/647 {Blood coagulation factors not
provided for in a preceding group or
according to more than one of the
preceding groups}
- 9/6472 {Cysteine endopeptidases (3.4.22)}
- 9/6475 {Interleukin 1-beta convertase-
like enzymes (3.4.22.10; 3.4.22.36;
3.4.22.63)}
- 9/6478 {Aspartic endopeptidases (3.4.23)}
- 9/6481 {Pepsins (3.4.23.1; 3.4.23.2;
3.4.23.3)}
- 9/6483 {Chymosin (3.4.23.4), i.e. rennin}
- 9/6486 {Renin (3.4.23.15)}
- 9/6489 {Metalloendopeptidases (3.4.24)}
- 9/6491 {Matrix metalloproteases [MMP's],
e.g. interstitial collagenase (3.4.24.7);
Stromelysins (3.4.24.17; 3.2.1.22);
Matrilysin (3.4.24.23)}
- 9/6494 {Nepriylsin (3.4.24.11), i.e.
enkephalinase or neutral-
endopeptidase 24.11}
- 9/6497 {Endothelin-converting enzyme
(3.4.24.71)}
- 9/78 . . . acting on carbon to nitrogen bonds other than
peptide bonds (3.5)
- 9/80 . . . acting on amide bonds in linear amides
{(3.5.1)}
- 9/82 Asparaginase {(3.5.1.1)}
- 9/84 Penicillin amidase {(3.5.1.11)}
- 9/86 . . . acting on amide bonds in cyclic amides, e.g.
penicillinase {(3.5.2)}
- 9/88 . . . Lyases (4.)
- 9/90 . . . Isomerases (5.)
- 9/92 . . . Glucose isomerase {(5.3.1.5; 5.3.1.9; 5.3.1.18)}
- 9/93 . . . {Ligases (6)}
- 9/94 . . . Pancreatin
- 9/96 . . . Stabilising an enzyme by forming an adduct or a
composition; Forming enzyme conjugates
- 9/98 . . . Preparation of granular or free-flowing enzyme
compositions ([C12N 9/96 takes precedence](#))
- 9/99 . . . Enzyme inactivation by chemical treatment
- 11/00 Carrier-bound or immobilised enzymes; Carrier-
bound or immobilised microbial cells; Preparation
thereof**
- 11/02 . . . Enzymes or microbial cells immobilised on or in an
organic carrier
- 11/04 . . . entrapped within the carrier, e.g. gel or hollow
fibres
- 11/06 . . . attached to the carrier via a bridging agent
- 11/08 . . . the carrier being a synthetic polymer
- 11/082 obtained by reactions only involving carbon-to-
carbon unsaturated bonds
- 11/084 Polymers containing vinyl alcohol units
- 11/087 Acrylic polymers
- 11/089 obtained otherwise than by reactions only
involving carbon-to-carbon unsaturated bonds
- 11/091 Phenol resins; Amino resins
- 11/093 Polyurethanes
- 11/096 Polyesters; Polyamides
- 11/098 formed in the presence of the enzymes or
microbial cells
- 11/10 . . . the carrier being a carbohydrate
- 11/12 . . . Cellulose or derivatives thereof
- 11/14 . . . Enzymes or microbial cells immobilised on or in an
inorganic carrier
- 11/16 . . . Enzymes or microbial cells immobilised on or in a
biological cell
- 11/18 . . . Multi-enzyme systems
- 13/00 Treatment of microorganisms or enzymes with
electrical or wave energy, e.g. magnetism, sonic
waves**
- 15/00 Mutation or genetic engineering; DNA or RNA
concerning genetic engineering, vectors, e.g.
plasmids, or their isolation, preparation or
purification; Use of hosts therefor (mutants or
genetically engineered microorganisms, per se
[C12N 1/00](#), [C12N 5/00](#), [C12N 7/00](#); new plants per se
[A01H 4/00](#); plant reproduction by tissue culture techniques
[A01H 4/00](#); new animals per se [A01K 67/00](#); use of
medicinal preparations containing genetic material
which is inserted into cells of the living body to treat
genetic diseases, gene therapy [A61K 48/00](#))**
- 15/01 . . . Preparation of mutants without inserting foreign
genetic material therein; Screening processes
therefor
- 15/02 . . . Preparation of hybrid cells by fusion of two or more
cells, e.g. protoplast fusion {([monoclonal antibodies](#)
[C07K 16/00](#); apparatus for cell fusion [C12M](#))}
- 15/03 . . . Bacteria
- 15/04 . . . Fungi
- 15/09 . . . Recombinant DNA-technology

- 15/10 . . . Processes for the isolation, preparation or purification of DNA or RNA ([chemical preparation of DNA or RNA C07H 21/00](#); [preparation of non-structural polynucleotides from microorganisms or with enzymes C12P 19/34](#))
- NOTE**
{In groups [C12N 15/10](#) - [C12N 15/1096](#), C-Sets are used for classification. The detailed information about the C-Sets construction and the associated syntax rules are found in the Definitions of [C12N](#)}.
- 15/1003 . . . {Extracting or separating nucleic acids from biological samples, e.g. pure separation or isolation methods; Conditions, buffers or apparatuses therefor}
- 15/1006 {by means of a solid support carrier, e.g. particles, polymers}
- 15/101 {by chromatography, e.g. electrophoresis, ion-exchange, reverse phase}
- 15/1013 {by using magnetic beads}
- 15/1017 {by filtration, e.g. using filters, frits, membranes}
- 15/102 . . . {Mutagenizing nucleic acids}
- 15/1024 {*In vivo* mutagenesis using high mutation rate "mutator" host strains by inserting genetic material, e.g. encoding an error prone polymerase, disrupting a gene for mismatch repair}
- 15/1027 {by DNA shuffling, e.g. RSR, STEP, RPR}
- 15/1031 {mutagenesis by gene assembly, e.g. assembly by oligonucleotide extension PCR}
- 15/1034 . . . {Isolating an individual clone by screening libraries}
- 15/1037 {Screening libraries presented on the surface of microorganisms, e.g. phage display, E. coli display}
- 15/1041 {Ribosome/Polysome display, e.g. SPERT, ARM}
- 15/1044 {Preparation or screening of libraries displayed on scaffold proteins}
- 15/1048 {SELEX}
- 15/1051 {Gene trapping, e.g. exon-, intron-, IRES-, signal sequence-trap cloning, trap vectors}
- 15/1055 {Protein x Protein interaction, e.g. two hybrid selection}
- 15/1058 {Directional evolution of libraries, e.g. evolution of libraries is achieved by mutagenesis and screening or selection of mixed population of organisms}
- 15/1062 {mRNA-Display, e.g. polypeptide and encoding template are connected covalently}
- 15/1065 {Preparation or screening of tagged libraries, e.g. tagged microorganisms by STM-mutagenesis, tagged polynucleotides, gene tags}
- 15/1068 {Template (nucleic acid) mediated chemical library synthesis, e.g. chemical and enzymatical DNA-templated organic molecule synthesis, libraries prepared by non ribosomal polypeptide synthesis [NRPS], DNA/RNA-polymerase mediated polypeptide synthesis}
- 15/1072 {Differential gene expression library synthesis, e.g. subtracted libraries, differential screening}
- 15/1075 {by coupling phenotype to genotype, not provided for in other groups of this subclass}
- 15/1079 {Screening libraries by altering the phenotype or phenotypic trait of the host ([reporter assays C12N 15/1086](#))}
- 15/1082 {Preparation or screening gene libraries by chromosomal integration of polynucleotide sequences, HR-, site-specific-recombination, transposons, viral vectors}
- 15/1086 {Preparation or screening of expression libraries, e.g. reporter assays}
- 15/1089 {Design, preparation, screening or analysis of libraries using computer algorithms}
- 15/1093 {General methods of preparing gene libraries, not provided for in other subgroups}
- 15/1096 {cDNA Synthesis; Subtracted cDNA library construction, e.g. RT, RT-PCR}
- 15/11 . . . DNA or RNA fragments; Modified forms thereof ([DNA or RNA not used in recombinant technology, C07H 21/00](#)); {Non-coding nucleic acids having a biological activity}
- NOTE**
Documents relating to DNA or its corresponding RNA and their use in recombinant DNA technology or the preparation of specific peptides, e.g. enzymes, are classified in subclass [C07K](#) or in group [C12N 9/00](#) according to the peptides, with the appropriate indexing codes relating to their use in recombinant technology. Groups [C12N 15/11](#) - [C12N 15/117](#) cover also the use of non-coding nucleic acids as active ingredients in medicinal preparations. The [C12N 2303/00](#) ICO scheme has to be applied to these groups. When documents classifiable in one or more subgroups disclose general principles of the technology applicable to the whole field, classification is also made in group [C12N 15/111](#)
- 15/111 {General methods applicable to biologically active non-coding nucleic acids}
- 15/113 Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; {Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing ([when used in plants C12N 15/8218](#))}
- 15/1131 {against viruses}
- 15/1132 {against retroviridae, e.g. HIV}
- 15/1133 {against herpesviridae, e.g. HSV}
- 15/1135 {against oncogenes or tumor suppressor genes}
- 15/1136 {against growth factors, growth regulators, cytokines, lymphokines or hormones}
- 15/1137 {against enzymes ([viral enzymes C12N 15/1131](#); [receptors C12N 15/1138](#))}
- 15/1138 {against receptors or cell surface proteins}

- 15/115 . . . Aptamers, i.e. nucleic acids binding a target molecule specifically and with high affinity without hybridising therewith {; Nucleic acids binding to non-nucleic acids, e.g. aptamers}
- NOTE**
- Aptamers fused to compounds which are already classified in groups [C12N 15/11](#) - [C12N 15/117](#), are classified with the corresponding compound
- 15/117 . . . Nucleic acids having immunomodulatory properties, e.g. containing CpG-motifs
- 15/52 . . . Genes encoding for enzymes or proenzymes
- NOTE**
- In this group genes encoding for proenzymes are classified with the corresponding genes encoding enzymes.
- 15/62 . . . DNA sequences coding for fusion proteins
- NOTE**
- In this group, the following term is used with the meaning indicated:
- "fusion" means the fusion of two different proteins.
- 15/625 . . . {containing a sequence coding for a signal sequence}
- 15/63 . . Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- 15/635 . . . {Externally inducible repressor mediated regulation of gene expression, e.g. tetR inducible by tetracycline}
- 15/64 . . . General methods for preparing the vector, for introducing it into the cell or for selecting the vector-containing host
- NOTE**
- {In the group [C12N 15/64](#), C-Sets are used for classification. The detailed information about the C-Sets construction and the associated syntax rules are found in the Definitions of [C12N](#)}
- 15/65 . . . using markers (enzymes used as markers [C12N 15/52](#))
- NOTE**
- {In the group [C12N 15/65](#), C-Sets are used for classification. The detailed information about the C-Sets construction and the associated syntax rules are found in the Definitions of [C12N](#)}
- 15/66 . . . General methods for inserting a gene into a vector to form a recombinant vector using cleavage and ligation; Use of non-functional linkers or adaptors, e.g. linkers containing the sequence for a restriction endonuclease
- NOTES**
- In this group, the following expression is used with the meaning indicated:
 - "non-functional linkers" means DNA sequences which are used to link DNA sequences and which have no known function of structural gene or regulating function.
 - {In the group [C12N 15/66](#), C-Sets are used for classification. The detailed information about the C-Sets construction and the associated syntax rules are found in the Definitions of [C12N](#)}
- 15/67 . . . General methods for enhancing the expression
- 15/68 Stabilisation of the vector
- 15/69 Increasing the copy number of the vector
- 15/70 . . . Vectors or expression systems specially adapted for E. coli
- NOTES**
- This group covers the use of E. coli as host.
 - Shuttle vectors also replicating in E. coli are classified according to the other host.
- 15/71 Expression systems using regulatory sequences derived from the trp-operon
- 15/72 Expression systems using regulatory sequences derived from the lac-operon
- 15/73 Expression systems using phage (lambda) regulatory sequences
- 15/74 . . . Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora
- NOTE**
- This group covers the use of prokaryotes as hosts.
- 15/743 {for Agrobacterium; Rhizobium; Bradyrhizobium}
- 15/746 {for lactic acid bacteria (Streptococcus; Lactococcus; Lactobacillus; Pediococcus; Enterococcus; Leuconostoc; Propionibacterium; Bifidobacterium; Sporolactobacillus)}
- 15/75 for Bacillus
- 15/76 for Actinomyces; for Streptomyces
- 15/77 for Corynebacterium; for Brevibacterium
- 15/78 for Pseudomonas
- 15/79 . . . Vectors or expression systems specially adapted for eukaryotic hosts
- NOTE**
- This group covers the use of eukaryotes as hosts.
- 15/80 for fungi
- 15/81 for yeasts
- 15/815 {for yeasts other than Saccharomyces}
- 15/82 for plant cells {, e.g. plant artificial chromosomes (PACs)}
- WARNING**
- Documents are being continuously reclassified into this new classification scheme. See Warning notes below
- 15/8201 {Methods for introducing genetic material into plant cells, e.g. DNA, RNA, stable or transient incorporation, tissue culture methods adapted for transformation}

| | | | |
|---------|---|---------|--|
| 15/8202 | {by biological means, e.g. cell mediated or natural vector} | 15/8235 | {Fruit-specific} |
| 15/8203 | {Virus mediated transformation} | 15/8237 | {Externally regulated expression systems} |
| 15/8205 | {Agrobacterium mediated transformation} | 15/8238 | {chemically inducible, e.g. tetracycline} |
| 15/8206 | {by physical or chemical, i.e. non-biological, means, e.g. electroporation, PEG mediated} | 15/8239 | {pathogen inducible} |
| 15/8207 | {by mechanical means, e.g. microinjection, particle bombardment, silicon whiskers} | 15/8241 | {Phenotypically and genetically modified plants via recombinant DNA technology} |
| 15/8209 | {Selection, visualisation of transformants, reporter constructs, e.g. antibiotic resistance markers} | 15/8242 | {with non-agronomic quality (output) traits, e.g. for industrial processing; Value added, non-agronomic traits} |
| | NOTE | 15/8243 | {involving biosynthetic or metabolic pathways, i.e. metabolic engineering, e.g. nicotine, caffeine} |
| | Standard selectable markers such as neomycin phosphotransferase (NPT) are not systematically classified in C12N 15/8209 | 15/8245 | {involving modified carbohydrate or sugar alcohol metabolism, e.g. starch biosynthesis} |
| 15/821 | {Non-antibiotic resistance markers, e.g. morphogenetic, metabolic markers} | 15/8246 | {Non-starch polysaccharides, e.g. cellulose, fructans, levans} |
| 15/8212 | {Colour markers, e.g. beta-glucuronidase [GUS], green fluorescent protein [GFP], carotenoid} | 15/8247 | {involving modified lipid metabolism, e.g. seed oil composition} |
| 15/8213 | {Targeted insertion of genes into the plant genome by homologous recombination} | 15/8249 | {involving ethylene biosynthesis, senescence or fruit development, e.g. modified tomato ripening, cut flower shelf-life} |
| 15/8214 | {Plastid transformation} | 15/825 | {involving pigment biosynthesis} |
| 15/8216 | {Methods for controlling, regulating or enhancing expression of transgenes in plant cells} | | NOTE |
| 15/8217 | {Gene switch} | | Transgenic plants with altered flower morphology are also classified in this group |
| 15/8218 | {Antisense, co-suppression, viral induced gene silencing [VIGS], post-transcriptional induced gene silencing [PTGS]} | 15/8251 | {Amino acid content, e.g. synthetic storage proteins, altering amino acid biosynthesis} |
| 15/822 | {Reducing position variability, e.g. by the use of scaffold attachment region/matrix attachment region (SAR/MAR); Use of SAR/MAR to regulate gene expression} | 15/8253 | {Methionine or cysteine} |
| 15/8221 | {Transit peptides} | 15/8254 | {Tryptophan or lysine} |
| 15/8222 | {Developmentally regulated expression systems, tissue, organ specific, temporal or spatial regulation} | 15/8255 | {involving lignin biosynthesis} |
| 15/8223 | {Vegetative tissue-specific promoters} | 15/8257 | {for the production of primary gene products, e.g. pharmaceutical products, interferon} |
| 15/8225 | {Leaf-specific, e.g. including petioles, stomata} | 15/8258 | {for the production of oral vaccines (antigens) or immunoglobulins} |
| 15/8226 | {Stem-specific, e.g. including tubers, beets} | 15/8259 | {Phytoremediation} |
| 15/8227 | {Root-specific} | 15/8261 | {with agronomic (input) traits, e.g. crop yield} |
| 15/8229 | {Meristem-specific, e.g. nodal, apical} | 15/8262 | {involving plant development} |
| 15/823 | {Reproductive tissue-specific promoters} | 15/8263 | {Ablation; Apoptosis} |
| 15/8231 | {Male-specific, e.g. anther, tapetum, pollen} | 15/8265 | {Transgene containment, e.g. gene dispersal} |
| 15/8233 | {Female-specific, e.g. pistil, ovule} | 15/8266 | {Abscission; Dehiscence; Senescence} |
| 15/8234 | {Seed-specific, e.g. embryo, endosperm} | 15/8267 | {Seed dormancy, germination or sprouting} |
| | | 15/8269 | {Photosynthesis} |
| | | 15/827 | {Flower development or morphology, e.g. flowering promoting factor [FPF]} |
| | | 15/8271 | {for stress resistance, e.g. heavy metal resistance} |
| | | 15/8273 | {for drought, cold, salt resistance} |
| | | 15/8274 | {for herbicide resistance} |
| | | 15/8275 | {Glyphosate} |

| | | | | | |
|---------|-----------|---|----------------|-----------|--|
| 15/8277 | | {Phosphinotricin} | 15/8616 | | {Special methods for targeting systems} |
| 15/8278 | | {Sulfonylurea} | 15/863 | | Poxviral vectors, {e.g. entomopoxvirus} |
| 15/8279 | | {for biotic stress resistance, pathogen resistance, disease resistance} | 15/8633 | | {Avian poxviral vectors} |
| 15/8281 | | {for bacterial resistance} | 15/8636 | | {Vaccina virus vectors} |
| 15/8282 | | {for fungal resistance} | 15/864 | | Parvoviral vectors {, e.g. parvovirus, densovirus} |
| 15/8283 | | {for virus resistance} | 15/8645 | | {Adeno-associated virus} |
| 15/8285 | | {for nematode resistance} | 15/866 | | Baculoviral vectors |
| 15/8286 | | {for insect resistance} | 15/867 | | Retroviral vectors |
| 15/8287 | | {for fertility modification, e.g. apomixis} | 15/8673 | | {Special methods for packaging systems} |
| 15/8289 | | {Male sterility} | 15/8676 | | {Special methods for targeting systems} |
| 15/829 | | {Female sterility} | 15/869 | | Herpesviral vectors |
| 15/8291 | | {Hormone-influenced development} | 15/8695 | | {Herpes simplex virus-based vectors} |
| 15/8293 | | {Abscisic acid [ABA]} | 15/87 | | Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation |
| 15/8294 | | {Auxins} | 15/873 | | Techniques for producing new embryos, e.g. nuclear transfer, manipulation of totipotent cells or production of chimeric embryos |
| 15/8295 | | {Cytokinins} | 15/877 | | Techniques for producing new mammalian cloned embryos |
| 15/8297 | | {Gibberellins; GA3} | 15/8771 | | {Bovine embryos} |
| 15/8298 | | {Brassinosteroids} | 15/8772 | | {Caprine embryos} |
| 15/85 | | for animal cells | 15/8773 | | {Ovine embryos} |
| 15/8509 | | {for producing genetically modified animals, e.g. transgenic} | 15/8775 | | {Murine embryos} |
| | | | 15/8776 | | {Primate embryos} |
| | | | 15/8777 | | {Rabbit embryos} |
| | | | 15/8778 | | {Swine embryos} |
| | | | 15/88 | | using microencapsulation, e.g. using {amphiphile} liposome vesicle |
| | | | 15/89 | | using microinjection |
| | | | 15/895 | | {using biolistic methods} |
| | | | 15/90 | | Stable introduction of foreign DNA into chromosome |
| | | | 15/902 | | {using homologous recombination} |
| | | | 15/905 | | {in yeast} |
| | | | 15/907 | | {in mammalian cells} |
| | | | | | |
| | | | 2303/00 | | Indexing codes associated with general methodologies in the field of biologically active non-coding nucleic acids |
| | | | | | NOTE |
| | | | | | Indexing codes of group C12N 2303/00 are only used in combination with group C12N 15/111 |
| | | | 2310/00 | | Structure or type of the nucleic acid |
| | | | | | NOTE |
| | | | | | In groups C12N 2310/00 - C12N 2310/533 , C-Sets are used for classification. The detailed information about the C-Sets construction and the associated syntax rules are found in the Definitions of C12N . |
| | | | 2310/10 | | Type of nucleic acid |
| | | | 2310/11 | | Antisense |
| | | | 2310/111 | | spanning the whole gene, or a large part of it |
| | | | 2310/113 | | targeting other non-coding nucleic acids, e.g. antagonists |
| | | | 2310/12 | | catalytic nucleic acids, e.g. ribozymes |

NOTE

Additional aspects of the modified animals are classified in the groups [A01K 2207/00](#) - [A01K 2267/00](#)

WARNING

From March 15, 2012 groups [C12N 15/861](#) - [C12N 15/869](#) and subgroups thereof are no longer used for the classification of new documents. The documents in these (sub)groups are being reclassified to the corresponding codes in the range [C12N 2710/00](#)-[C12N 2795/00](#)

- 2310/121 . . . Hammerhead
- 2310/122 . . . Hairpin
- 2310/123 . . . Hepatitis delta
- 2310/124 . . . based on group I or II introns
- 2310/1241 Tetrahymena
- 2310/126 . . . involving RNase P
- 2310/127 . . . DNAzymes
- 2310/128 . . . processing or releasing ribozyme
- 2310/13 . . Decoys
- 2310/14 . . interfering N.A.
- 2310/141 . . . MicroRNAs, miRNAs
- 2310/15 . . Nucleic acids forming more than 2 strands, e.g. TFOs
- 2310/151 . . . more than 3 strands, e.g. tetrads, H-DNA
- 2310/152 . . . on a single-stranded target, e.g. fold-back TFOs
- 2310/153 . . . with the aid of a protein, e.g. recombinase
- 2310/16 . . Aptamers
- 2310/17 . . Immunomodulatory nucleic acids
- 2310/18 . . acting by a non-sequence specific mechanism
(other than C12N 2310/16 or C12N 2310/17)
- 2310/20 . . involving clustered regularly interspaced short palindromic repeats [CRISPRs]
- 2310/30 . Chemical structure
- 2310/31 . . of the backbone
- 2310/311 . . . Phosphotriesters
- 2310/312 . . . Phosphonates
- 2310/3125 Methylphosphonates
- 2310/313 . . . Phosphorodithioates
- 2310/314 . . . Phosphoramidates
- 2310/3145 with the nitrogen in 3' or 5'-position
- 2310/315 . . . Phosphorothioates
- 2310/316 . . . Phosphonothioates
- 2310/317 . . . with an inverted bond, e.g. a cap structure
- 2310/318 . . . where the PO2 is completely replaced, e.g. MMI or formacetal
- 2310/3181 Peptide nucleic acid, PNA
- 2310/3183 Diol linkers, e.g. glycols or propanediols
- 2310/319 . . . linked by 2'-5' linkages, i.e. having a free 3'-position
- 2310/32 . . of the sugar
- 2310/321 . . . 2'-O-R Modification
- 2310/322 . . . 2'-R Modification
- 2310/323 . . . modified ring structure
- 2310/3231 having an additional ring, e.g. LNA, ENA
- 2310/3233 Morpholino-type ring
- 2310/3235 having the O of the ribose replaced by another atom
- 2310/33 . . of the base
- 2310/331 . . . Universal or degenerate base
- 2310/332 . . . Abasic residue
- 2310/333 . . . Modified A
- 2310/334 . . . Modified C
- 2310/3341 5-Methylcytosine
- 2310/335 . . . Modified T or U
- 2310/336 . . . Modified G
- 2310/337 . . . in alpha-anomeric form
- 2310/34 . . Spatial arrangement of the modifications
- 2310/341 . . . Gapmers, i.e. of the type =====
- 2310/342 . . . Hemimers, i.e. of the type =====
- 2310/343 . . . having patterns, e.g. =====
- 2310/344 . . . Position-specific modifications, e.g. on every purine, at the 3'-end
- 2310/345 . . . having at least two different backbone modifications
- 2310/346 . . . having a combination of backbone and sugar modifications
- 2310/35 . . Nature of the modification
- 2310/351 . . . Conjugate
- 2310/3511 intercalating or cleaving agent
- 2310/3513 Protein; Peptide
- 2310/3515 Lipophilic moiety, e.g. cholesterol
- 2310/3517 Marker; Tag
- 2310/3519 Fusion with another nucleic acid
- 2310/352 . . . linked to the nucleic acid via a carbon atom
- 2310/3521 Methyl
- 2310/3523 Allyl
- 2310/3525 MOE, methoxyethoxy
- 2310/3527 Other alkyl chain
- 2310/3529 Aromatic substituent
- 2310/353 . . . linked to the nucleic acid via an atom other than carbon
- 2310/3531 Hydrogen
- 2310/3533 Halogen
- 2310/3535 Nitrogen
- 2310/50 . Physical structure
- 2310/51 . . in polymeric form, e.g. multimers, concatemers
- 2310/52 . . branched
- 2310/53 . . partially self-complementary or closed
- 2310/531 . . . Stem-loop; Hairpin
- 2310/532 . . . Closed or circular
- 2310/533 . . . having a mismatch or nick in at least one of the strands
- 2320/00 Applications; Uses**
- 2320/10 . in screening processes
- 2320/11 . . for the determination of target sites, i.e. of active nucleic acids
- 2320/12 . . in functional genomics, i.e. for the determination of gene function
- 2320/13 . . in a process of directed evolution, e.g. SELEX, acquiring a new function
- 2320/30 . Special therapeutic applications
- 2320/31 . . Combination therapy
- 2320/32 . . Special delivery means, e.g. tissue-specific
- 2320/33 . . Alteration of splicing
- 2320/34 . . Allele or polymorphism specific uses
- 2320/35 . . based on a specific dosage / administration regimen
- 2320/50 . Methods for regulating/modulating their activity
- 2320/51 . . modulating the chemical stability, e.g. nuclease-resistance
- 2320/52 . . modulating the physical stability, e.g. GC-content
- 2320/53 . . reducing unwanted side-effects
- 2330/00 Production**
- 2330/10 . naturally occurring
- 2330/30 . chemically synthesised
- 2330/31 . . Libraries, arrays
- 2330/50 . Biochemical production, i.e. in a transformed host cell
- 2330/51 . . Specially adapted vectors
- 2500/00 Specific components of cell culture medium**
- 2500/02 . Atmosphere, e.g. low oxygen conditions
- 2500/05 . Inorganic components

C12N

- 2500/10 . . Metals; Metal chelators ([cobalamine C12N 2500/38](#))
 - 2500/12 . . . Light metals, i.e. alkali, alkaline earth, Be, Al, Mg
 - 2500/14 Calcium; Ca chelators; Calcitonin
 - 2500/16 Magnesium; Mg chelators
 - 2500/20 . . . Transition metals
 - 2500/22 Zinc; Zn chelators ([insulin-zinc complexes C12N 2501/33](#))
 - 2500/24 Iron; Fe chelators; Transferrin
 - 2500/25 Insulin-transferrin; Insulin-transferrin-selenium
 - 2500/30 . Organic components ([metal chelators C12N 2500/10](#); [calcitonin C12N 2500/14](#); [transferrin C12N 2500/24](#))
 - 2500/32 . . Amino acids
 - 2500/33 . . . other than alpha-amino carboxylic acids, e.g. beta-amino acids, taurine
 - 2500/34 . . Sugars
 - 2500/35 . . Polyols, e.g. glycerin, inositol
 - 2500/36 . . Lipids
 - 2500/38 . . Vitamins
 - 2500/40 . . Nucleotides, nucleosides, bases ([cyclic nucleotides C12N 2501/01](#), [anti-neoplastic drugs C12N 2501/06](#))
 - 2500/42 . . Organic phosphate, e.g. beta glycerophosphate
 - 2500/44 . . Thiols, e.g. mercaptoethanol
 - 2500/46 . . Amines, e.g. putrescine
 - 2500/50 . Soluble polymers, e.g. polyethyleneglycol [PEG]
 - 2500/60 . Buffer, e.g. pH regulation, osmotic pressure
 - 2500/62 . . DMSO
 - 2500/70 . Undefined extracts ([conditioned medium C12N 2502/00](#))
 - 2500/72 . . from bacteria
 - 2500/74 . . from fungi, e.g. yeasts
 - 2500/76 . . from plants
 - 2500/78 . . from protozoa
 - 2500/80 . . from animals
 - 2500/82 . . . from invertebrates
 - 2500/84 . . . from mammals
 - 2500/90 . Serum-free medium, which may still contain naturally-sourced components
 - 2500/92 . . Medium free of human- or animal-derived components
 - 2500/95 . . Protein-free medium and culture conditions
 - 2500/98 . Xeno-free medium and culture conditions
 - 2500/99 . Serum-free medium
- WARNING**
- This group is no longer used for the classification of new documents as from January 1, 2012. The backlog of this group is being continuously reclassified to [C12N 2500/90](#) - [C12N 2500/98](#)
- 2501/00** **Active agents used in cell culture processes, e.g. differentiation**
- NOTE**
- Whenever possible, indexation is done by signalling pathway and not by chemical structure, e.g. the group of a protein covers not only peptide analogs of it and the corresponding nucleic acids, as in [C07K 14/00](#), but also antibodies, anti-idiotypic antibodies, non-peptide ligands of the receptor, the receptor itself, antibodies against the receptor or inhibitors of the conversion enzyme which processes the protein precursor. Unless otherwise provided for, ligands and substrates take precedence over receptors and enzymes.
- 2501/01 . Modulators of cAMP or cGMP, e.g. non-hydrolysable analogs, phosphodiesterase inhibitors, cholera toxin
 - 2501/02 . Compounds of the arachidonic acid pathway, e.g. prostaglandins, leukotrienes
 - 2501/03 . Compounds acting on the NO pathway, e.g. nitrososarginine
 - 2501/04 . Immunosuppressors, e.g. cyclosporin, tacrolimus
 - 2501/05 . Adjuvants
 - 2501/051 . . Lipid A (MPA, MPL)
 - 2501/052 . . Lipopolysaccharides [LPS]
 - 2501/054 . . Muramyle peptides
 - 2501/056 . . Immunostimulating oligonucleotides, e.g. CpG
 - 2501/06 . Anti-neoplastic drugs, anti-retroviral drugs, e.g. azacytidine, cyclophosphamide
 - 2501/065 . Modulators of histone acetylation
 - 2501/07 . Heat shock proteins
 - 2501/10 . Growth factors
 - 2501/105 . . Insulin-like growth factors [IGF]
 - 2501/11 . . Epidermal growth factor [EGF]
 - 2501/113 . . Acidic fibroblast growth factor (aFGF, FGF-1)
 - 2501/115 . . Basic fibroblast growth factor (bFGF, FGF-2)
 - 2501/117 . . Keratinocyte growth factors (KGF-1, i.e. FGF-7; KGF-2, i.e. FGF-12)
 - 2501/119 . . Other fibroblast growth factors, e.g. FGF-4, FGF-8, FGF-10
 - 2501/12 . . Hepatocyte growth factor [HGF]
 - 2501/125 . . Stem cell factor [SCF], c-kit ligand [KL]
 - 2501/13 . . Nerve growth factor [NGF]; Brain-derived neurotrophic factor [BDNF]; Ciliary neurotrophic factor [CNTF]; Glial-derived neurotrophic factor [GDNF]; Neurotrophins [NT]; Neuregulins
 - 2501/135 . . Platelet-derived growth factor [PDGF]
 - 2501/14 . . Erythropoietin [EPO]
 - 2501/145 . . Thrombopoietin [TPO]
 - 2501/148 . . Transforming growth factor alpha [TGF-a]
 - 2501/15 . . Transforming growth factor beta (TGF-β)
 - 2501/155 . . Bone morphogenic proteins [BMP]; Osteogenins; Osteogenic factor; Bone inducing factor
 - 2501/16 . . Activin; Inhibin; Mullerian inhibiting substance
 - 2501/165 . . Vascular endothelial growth factor [VEGF]
 - 2501/17 . . Angiopoietin
 - 2501/175 . . Cardiotrophin
 - 2501/18 . . Liver cell growth factor (LCGF, Gly-His-Lys)
 - 2501/185 . . Osteoprotegerin; Osteoclast differentiation factor (ODF, RANKL)
 - 2501/19 . . Growth and differentiation factors [GDF]
 - 2501/195 . . Heregulin, neu differentiation factor
 - 2501/20 . Cytokines; Chemokines
 - 2501/21 . . Chemokines, e.g. MIP-1, MIP-2, RANTES, MCP, PF-4
 - 2501/22 . . Colony stimulating factors (G-CSF, GM-CSF)
 - 2501/23 . . Interleukins [IL]
 - 2501/2301 . . . Interleukin-1 (IL-1)
 - 2501/2302 . . . Interleukin-2 (IL-2)
 - 2501/2303 . . . Interleukin-3 (IL-3)

C12N

| | | | | | |
|-----------|-------|--|----------|---------|---|
| 2501/2304 | . . . | Interleukin-4 (IL-4) | 2501/385 | . . . | of the family of the retinoic acid receptor, e.g. RAR, RXR; Peroxisome proliferator-activated receptor [PPAR] |
| 2501/2305 | . . . | Interleukin-5 (IL-5) | 2501/39 | . . . | Steroid hormones |
| 2501/2306 | . . . | Interleukin-6 (IL-6) | 2501/392 | | Sexual steroids |
| 2501/2307 | . . . | Interleukin-7 (IL-7) | 2501/395 | . . . | Thyroid hormones |
| 2501/2308 | . . . | Interleukin-8 (IL-8) | 2501/40 | . | Regulators of development |
| 2501/2309 | . . . | Interleukin-9 (IL-9) | 2501/405 | . . | Cell cycle regulated proteins, e.g. cyclins, cyclin-dependant kinases |
| 2501/231 | . . . | Interleukin-10 (IL-10) | 2501/41 | . . | Hedgehog proteins; Cyclopamine (inhibitor) |
| 2501/2311 | . . . | Interleukin-11 (IL-11) | 2501/415 | . . | Wnt; Frizzled |
| 2501/2312 | . . . | Interleukin-12 (IL-12) | 2501/42 | . . | Notch; Delta; Jagged; Serrate |
| 2501/2313 | . . . | Interleukin-13 (IL-13) | 2501/48 | . . | Regulators of apoptosis |
| 2501/2314 | . . . | Interleukin-14 (IL-14) | 2501/50 | . | Cell markers; Cell surface determinants |
| 2501/2315 | . . . | Interleukin-15 (IL-15) | 2501/505 | . . | CD4; CD8 |
| 2501/2316 | . . . | Interleukin-16 (IL-16) | 2501/51 | . . | B7 molecules, e.g. CD80, CD86, CD28 (ligand), CD152 (ligand) |
| 2501/2317 | . . . | Interleukin-17 (IL-17) | 2501/515 | . . | CD3, T-cell receptor complex |
| 2501/2318 | . . . | Interleukin-18 (IL-18) | 2501/52 | . . | CD40, CD40-ligand (CD154) |
| 2501/2319 | . . . | Interleukin-19 (IL-19) | 2501/53 | . . | CD2 |
| 2501/232 | . . . | Interleukin-20 (IL-20) | 2501/58 | . . | Adhesion molecules, e.g. ICAM, VCAM, CD18 (ligand), CD11 (ligand), CD49 (ligand) |
| 2501/2321 | . . . | Interleukin-21 (IL-21) | 2501/585 | . . | Integrins |
| 2501/2322 | . . . | Interleukin-22 (IL-22) | 2501/59 | . . | Lectins |
| 2501/2323 | . . . | Interleukin-23 (IL-23) | 2501/599 | . . | with CD designations not provided for elsewhere |
| 2501/2324 | . . . | Interleukin-24 (IL-24) | 2501/60 | . | Transcription factors |
| 2501/2325 | . . . | Interleukin-25 (IL-25) | 2501/602 | . . | Sox-2 |
| 2501/2326 | . . . | Interleukin-26 (IL-26) | 2501/603 | . . | Oct-3/4 |
| 2501/2327 | . . . | Interleukin-27 (IL-27) | 2501/604 | . . | Klf-4 |
| 2501/2328 | . . . | Interleukin-28 (IL-28) | 2501/605 | . . | Nanog |
| 2501/2329 | . . . | Interleukin-29 (IL-29) | 2501/606 | . . | c-Myc |
| 2501/233 | . . . | Interleukin-30 (IL-30) | 2501/608 | . . | Lin28 |
| 2501/2331 | . . . | Interleukin-31 (IL-31) | 2501/65 | . | MicroRNA |
| 2501/2332 | . . . | Interleukin-32 (IL-32) | 2501/70 | . | Enzymes |
| 2501/2333 | . . . | Interleukin-33 (IL-33) | 2501/71 | . . | Oxidoreductases (EC 1.) |
| 2501/2334 | . . . | Interleukin-34 (IL-34) | 2501/72 | . . | Transferases (EC 2.) (acetylation of histones C12N 2501/065) |
| 2501/2335 | . . . | Interleukin-35 (IL-35) | 2501/724 | . . . | Glycosyltransferases (EC 2.4.) |
| 2501/235 | . . . | Leukemia inhibitory factor [LIF] | 2501/727 | . . . | Kinases (EC 2.7.) |
| 2501/237 | . . | Oncostatin M [OSM] | 2501/73 | . . | Hydrolases (EC 3.) |
| 2501/24 | . . | Interferons [IFN] | 2501/734 | . . . | Proteases (EC 3.4.) |
| 2501/25 | . . | Tumour necrosing factors [TNF] | 2501/80 | . | Neurotransmitters; Neurohormones |
| 2501/26 | . . | Flt-3 ligand (CD135L, flk-2 ligand) | 2501/805 | . . | Acetylcholine |
| 2501/30 | . | Hormones (derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin C12N 2501/85) | 2501/81 | . . | Adrenaline |
| 2501/305 | . . | Growth hormone [GH], aka. somatotropin | 2501/815 | . . | Dopamine |
| 2501/31 | . . | Pituitary sex hormones, e.g. follicle-stimulating hormone [FSH], luteinising hormone [LH]; Chorionic gonadotropins | 2501/82 | . . | Histamine |
| 2501/315 | . . | Prolactin | 2501/825 | . . | Serotonine (5-HT); Melatonin |
| 2501/32 | . . | Angiotensins [AT], angiotensinogen | 2501/83 | . . | Tachykinins, e.g. substance P |
| 2501/33 | . . | Insulin (together with transferrin C12N 2500/25; Insulin-like growth factors C12N 2501/105) | 2501/835 | . . | Neuropeptide Y [NPY]; Peptide YY [PYY] |
| 2501/335 | . . | Glucagon; Glucagon-like peptide [GLP]; Exendin | 2501/84 | . . | Excitatory amino acids |
| 2501/34 | . . | Calcitonin; Calcitonin-gene related peptide [CGRO]; Amylin | 2501/845 | . . | Gamma amino butyric acid [GABA] |
| 2501/345 | . . | Gastrin; Cholecystokinins [CCK] | 2501/85 | . | Hormones derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin |
| 2501/35 | . . | Vasoactive intestinal peptide [VIP]; Pituitary adenylate cyclase activating polypeptide [PACAP] | 2501/855 | . . | Corticotropin [ACTH] |
| 2501/355 | . . | Leptin | 2501/86 | . . | Melanocyte-stimulating hormone [MSH] |
| 2501/36 | . . | Somatostatin | 2501/90 | . | Polysaccharides |
| 2501/365 | . . | Endothelin | 2501/905 | . . | Hyaluronic acid |
| 2501/37 | . . | Parathyroid hormone [PTH] | 2501/91 | . . | Heparin |
| 2501/375 | . . | Thyroid stimulating hormone [TSH] | 2501/998 | . | Proteins not provided for elsewhere |
| 2501/38 | . . | with nuclear receptors | | | |

NOTE

Classification by pathway does not apply.

2501/999 . Small molecules not provided for elsewhere

NOTE

Classification by pathway does not apply.

2502/00 Coculture with; Conditioned medium produced by

2502/02 . embryonic cells

2502/025 . . extra-embryonic cells, e.g. amniotic epithelium, placental cells, Wharton's jelly

2502/03 . non-embryonic pluripotent stem cells

2502/04 . germ cells

2502/07 . endocrine cells

2502/072 . . adrenal cells

2502/074 . . pinealocytes

2502/076 . . pituitary cells

2502/078 . . thyroid, parathyroid cells

2502/08 . cells of the nervous system

2502/081 . . neurons

2502/083 . . sensory transducers

2502/085 . . eye cells

2502/086 . . glial cells

2502/088 . . neural stem cells

2502/09 . epidermal cells, skin cells, oral mucosa cells

2502/091 . . melanocytes

2502/092 . . hair cells

2502/094 . . keratinocytes

2502/095 . . mammary cells

2502/097 . . oral mucosa cells

2502/098 . . cells of secretory glands, e.g. parotid gland, salivary glands, sweat glands, lacrymal glands

2502/11 . blood or immune system cells

2502/1107 . . B cells

2502/1114 . . T cells

2502/1121 . . Dendritic cells

2502/1128 . . Erythrocytes

2502/1135 . . Granulocytes

2502/1142 . . Osteoclasts

2502/115 . . Platelets, megakaryocytes

2502/1157 . . Monocytes, macrophages

2502/1164 . . NK cells

2502/1171 . . Haematopoietic stem cells

2502/1178 . . Spleen cells

2502/1185 . . Thymus cells

2502/1192 . . Lymphatic cells

2502/13 . connective tissue cells; generic mesenchyme cells, e.g. so-called "embryonic fibroblasts"

2502/1305 . . Adipocytes

2502/1311 . . Osteocytes, osteoblasts, odontoblasts

2502/1317 . . Chondrocytes

2502/1323 . . Adult fibroblasts

2502/1329 . . Cardiomyocytes

2502/1335 . . Skeletal muscle cells, myocytes, myoblasts, myotubes

2502/1341 . . Tenocytes, cells from tendons and ligaments

2502/1347 . . Smooth muscle cells

2502/1352 . . Mesenchymal stem cells

2502/1358 . . . Bone marrow mesenchymal stem cells (BM- MSC)

2502/1364 . . . Dental pulp stem cells, dental follicle stem cells

2502/137 . . . Blood-borne mesenchymal stem cells, e.g. Msc from umbilical cord blood

2502/1376 . . . Mesenchymal stem cells from hair follicles

2502/1382 . . . Adipose-derived stem cells [ADSC], adipose stromal stem cells

2502/1388 . . . Mesenchymal stem cells from other natural sources

2502/1394 . . Bone marrow stromal cells; whole marrow

2502/14 . hepatocytes

2502/22 . pancreatic cells

2502/23 . Gastro-intestinal tract cells

2502/24 . Genital tract cells, non-germinal cells from gonads

2502/243 . . Cells of the female genital tract, non-germinal ovarian cells

2502/246 . . Cells of the male genital tract, non-germinal testis cells

2502/25 . Urinary tract cells, renal cells

2502/253 . . Bladder cells

2502/256 . . Renal cells

2502/27 . Lung cells, respiratory tract cells

2502/28 . Vascular endothelial cells

2502/30 . tumour cells

2502/45 . Artificially induced pluripotent stem cells

2502/50 . invertebrate cells

2502/70 . Non-animal cells

2502/99 . genetically modified cells

NOTE

Use [C12N 2501/00](#) to index the expressed products.

2503/00 Use of cells in diagnostics

2503/02 . Drug screening

2503/04 . Screening or testing on artificial tissues

2503/06 . . Screening or testing on artificial skin

2506/00 Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells

NOTE

This scheme indexes the starting point of a differentiation process and is used in combination with classification in [C12N 5/06](#) for the end product. Differentiation of a restricted progenitor cell into its expected progeny is not indexed. Differentiation of totipotent cells and dedifferentiation are always indexed.

2506/02 . from embryonic cells

2506/025 . . from extra-embryonic cells, e.g. trophoblast, placenta

2506/03 . from non-embryonic pluripotent stem cells

2506/04 . from germ cells

2506/07 . from endocrine cells

2506/072 . . from adrenal cells

2506/074 . . from pinealocytes

2506/076 . . from pituitary cells

2506/078 . . from thyroid, parathyroid cells

2506/08 . from cells of the nervous system

2506/09 . from epidermal cells, from skin cells, from oral mucosa cells

2506/091 . . from melanocytes

2506/092 . . from hair cells

2506/094 . . from keratinocytes

2506/095 . . from mammary cells

2506/097 . . from oral mucosa cells

- 2506/098 . . from cells of secretory glands, e.g. parotid gland, salivary glands, sweat glands, lacrymal glands
- 2506/11 . from blood or immune system cells
- 2506/115 . . from monocytes, from macrophages
- 2506/13 . from connective tissue cells, from mesenchymal cells
- 2506/1307 . . from adult fibroblasts
- 2506/1315 . . from cardiomyocytes
- 2506/1323 . . from skeletal muscle cells
- 2506/133 . . from tenocytes
- 2506/1338 . . from smooth muscle cells
- 2506/1346 . . from mesenchymal stem cells
- 2506/1353 . . . from bone marrow mesenchymal stem cells (BM-MSC)
- 2506/1361 . . . from dental pulp or dental follicle stem cells
- 2506/1369 . . . from blood-borne mesenchymal stem cells, e.g. MSC from umbilical blood
- 2506/1376 . . . from mesenchymal stem cells derived from hair follicles
- 2506/1384 . . . from adipose-derived stem cells [ADSC], from adipose stromal stem cells
- 2506/1392 . . . from mesenchymal stem cells from other natural sources
- 2506/14 . from hepatocytes
- 2506/22 . from pancreatic cells
- 2506/23 . from cells of the gastro-intestinal tract
- 2506/24 . from cells of the genital tract, from non-germinal gonad cells
- 2506/243 . . from cells of the female genital tract cells, from non-germinal ovarian cells
- 2506/246 . . from cells of the male genital tract cells, from non-germinal testis cells
- 2506/25 . from renal cells, from cells of the urinary tract
- 2506/27 . from lung cells, from cells of the respiratory tract
- 2506/28 . from vascular endothelial cells
- 2506/30 . from cancer cells, e.g. reversion of tumour cells

NOTE

Unless the tumourigenic phenotype is totally reversed, the end product is still classified under [C12N 5/0693](#).

- 2506/45 . from artificially induced pluripotent stem cells
- 2509/00 Methods for the dissociation of cells, e.g. specific use of enzymes**
- 2509/10 . Mechanical dissociation
- 2510/00 Genetically modified cells**
- 2510/02 . Cells for production
- 2510/04 . Immortalised cells
- 2511/00 Cells for large scale production**
- 2513/00 3D culture**
- 2517/00 Cells related to new breeds of animals**
- 2517/02 . Cells from transgenic animals
- 2517/04 . Cells produced using nuclear transfer
- 2517/10 . Conditioning of cells for in vitro fecundation or nuclear transfer
- 2521/00 Culture process characterised by the use of hydrostatic pressure, flow or shear forces**
- 2521/10 . Sound, e.g. ultrasounds

- 2523/00 Culture process characterised by temperature**
- 2525/00 Culture process characterised by gravity, e.g. microgravity**
- 2527/00 Culture process characterised by the use of mechanical forces, e.g. strain, vibration**
- 2529/00 Culture process characterised by the use of electromagnetic stimulation**
- 2529/10 . Stimulation by light
- 2531/00 Microcarriers**
- 2533/00 Supports or coatings for cell culture, characterised by material**
- 2533/10 . Mineral substrates
- 2533/12 . . Glass
- 2533/14 . . Ceramic
- 2533/18 . . Calcium salts, e.g. apatite, Mineral components from bones, teeth, shells
- 2533/20 . Small organic molecules
- 2533/30 . Synthetic polymers ([thermoreactive polymers, e.g. PNIPAm, C12N 2539/10](#))
- 2533/32 . . Polylysine, polyornithine
- 2533/40 . . Polyhydroxyacids, e.g. polymers of glycolic or lactic acid (PGA, PLA, PLGA); Bioresorbable polymers
- 2533/50 . Proteins
- 2533/52 . . Fibronectin; Laminin
- 2533/54 . . Collagen; Gelatin
- 2533/56 . . Fibrin; Thrombin
- 2533/70 . Polysaccharides
- 2533/72 . . Chitin, chitosan
- 2533/74 . . Alginate
- 2533/76 . . Agarose, agar-agar
- 2533/78 . . Cellulose
- 2533/80 . . Hyaluronan
- 2533/90 . Substrates of biological origin, e.g. extracellular matrix, decellularised tissue
- 2533/92 . . Amnion; Decellularised dermis or mucosa
- 2535/00 Supports or coatings for cell culture characterised by topography**
- 2535/10 . Patterned coating
- 2537/00 Supports and/or coatings for cell culture characterised by physical or chemical treatment**
- 2537/10 . Cross-linking
- 2539/00 Supports and/or coatings for cell culture characterised by properties**
- 2539/10 . Coating allowing for selective detachment of cells, e.g. thermoreactive coating

Viruses

- 2710/00 dsDNA viruses**
- 2710/00011 . Details
- 2710/00021 . . Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2710/00022 . . New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2710/00023 . . Virus like particles [VLP]
- 2710/00031 . . Uses of virus other than therapeutic or vaccine, e.g. disinfectant

- 2710/00032 . . Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2710/00033 . . Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2710/00034 . . Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2710/00041 . . Use of virus, viral particle or viral elements as a vector
- 2710/00042 . . . virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2710/00043 . . . viral genome or elements thereof as genetic vector
- 2710/00044 . . . Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2710/00045 . . . Special targeting system for viral vectors
- 2710/00051 . . Methods of production or purification of viral material
- 2710/00052 . . . relating to complementing cells and packaging systems for producing virus or viral particles
- 2710/00061 . . Methods of inactivation or attenuation
- 2710/00062 . . . by genetic engineering
- 2710/00063 . . . by chemical treatment
- 2710/00064 . . . by serial passage
- 2710/00071 . . Demonstrated in vivo effect
- 2710/00088 . . for redistribution
- 2710/10011 . . Adenoviridae
- 2710/10021 . . . Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2710/10022 . . . New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2710/10023 . . . Virus like particles [VLP]
- 2710/10031 . . . Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2710/10032 . . . Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2710/10033 . . . Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2710/10034 . . . Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2710/10041 . . . Use of virus, viral particle or viral elements as a vector
- 2710/10042 virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2710/10043 viral genome or elements thereof as genetic vector
- 2710/10044 Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2710/10045 Special targeting system for viral vectors
- 2710/10051 Methods of production or purification of viral material
- 2710/10052 relating to complementing cells and packaging systems for producing virus or viral particles
- 2710/10061 Methods of inactivation or attenuation
- 2710/10062 by genetic engineering
- 2710/10063 by chemical treatment
- 2710/10064 by serial passage
- 2710/10071 Demonstrated in vivo effect
- 2710/10088 for redistribution
- 2710/10111 Atadenovirus, e.g. ovine adenovirus D
- 2710/10121 Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2710/10122 New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2710/10123 Virus like particles [VLP]
- 2710/10131 Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2710/10132 Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2710/10133 Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2710/10134 Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2710/10141 Use of virus, viral particle or viral elements as a vector
- 2710/10142 virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2710/10143 viral genome or elements thereof as genetic vector
- 2710/10144 Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2710/10145 Special targeting system for viral vectors
- 2710/10151 Methods of production or purification of viral material
- 2710/10152 relating to complementing cells and packaging systems for producing virus or viral particles
- 2710/10161 Methods of inactivation or attenuation
- 2710/10162 by genetic engineering
- 2710/10163 by chemical treatment
- 2710/10164 by serial passage
- 2710/10171 Demonstrated in vivo effect
- 2710/10188 for redistribution
- 2710/10211 Aviadenovirus, e.g. fowl adenovirus A
- 2710/10221 Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2710/10222 New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2710/10223 Virus like particles [VLP]
- 2710/10231 Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2710/10232 Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2710/10233 Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2710/10234 Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2710/10241 Use of virus, viral particle or viral elements as a vector
- 2710/10242 virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2710/10243 viral genome or elements thereof as genetic vector

- 2710/10244 Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2710/10245 Special targeting system for viral vectors
- 2710/10251 Methods of production or purification of viral material
- 2710/10252 relating to complementing cells and packaging systems for producing virus or viral particles
- 2710/10261 Methods of inactivation or attenuation
- 2710/10262 by genetic engineering
- 2710/10263 by chemical treatment
- 2710/10264 by serial passage
- 2710/10271 Demonstrated in vivo effect
- 2710/10288 for redistribution
- 2710/10311 . . . Mastadenovirus, e.g. human or simian adenoviruses
- 2710/10321 Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2710/10322 New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2710/10323 Virus like particles [VLP]
- 2710/10331 Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2710/10332 Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2710/10333 Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2710/10334 Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2710/10341 Use of virus, viral particle or viral elements as a vector
- 2710/10342 virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2710/10343 viral genome or elements thereof as genetic vector
- 2710/10344 Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2710/10345 Special targeting system for viral vectors
- 2710/10351 Methods of production or purification of viral material
- 2710/10352 relating to complementing cells and packaging systems for producing virus or viral particles
- 2710/10361 Methods of inactivation or attenuation
- 2710/10362 by genetic engineering
- 2710/10363 by chemical treatment
- 2710/10364 by serial passage
- 2710/10371 Demonstrated in vivo effect
- 2710/10388 for redistribution
- 2710/12011 . . . Asfarviridae
- 2710/12021 . . . Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2710/12022 . . . New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2710/12023 . . . Virus like particles [VLP]
- 2710/12031 . . . Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2710/12032 . . . Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2710/12033 . . . Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2710/12034 . . . Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2710/12041 . . . Use of virus, viral particle or viral elements as a vector
- 2710/12042 virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2710/12043 viral genome or elements thereof as genetic vector
- 2710/12044 Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2710/12045 Special targeting system for viral vectors
- 2710/12051 . . . Methods of production or purification of viral material
- 2710/12052 relating to complementing cells and packaging systems for producing virus or viral particles
- 2710/12061 . . . Methods of inactivation or attenuation
- 2710/12062 by genetic engineering
- 2710/12063 by chemical treatment
- 2710/12064 by serial passage
- 2710/12071 . . . Demonstrated in vivo effect
- 2710/12088 . . . for redistribution
- 2710/14011 . . . Baculoviridae
- 2710/14021 . . . Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2710/14022 . . . New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2710/14023 . . . Virus like particles [VLP]
- 2710/14031 . . . Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2710/14032 . . . Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2710/14033 . . . Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2710/14034 . . . Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2710/14041 . . . Use of virus, viral particle or viral elements as a vector
- 2710/14042 virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2710/14043 viral genome or elements thereof as genetic vectore
- 2710/14044 Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2710/14045 Special targeting system for viral vectors
- 2710/14051 . . . Methods of production or purification of viral material
- 2710/14052 relating to complementing cells and packaging systems for producing virus or viral particles
- 2710/14061 . . . Methods of inactivation or attenuation
- 2710/14062 by genetic engineering
- 2710/14063 by chemical treatment

- 2710/14064 by serial passage
- 2710/14071 . . . Demonstrated in vivo effect
- 2710/14088 . . . for redistribution
- 2710/14111 . . . Nucleopolyhedrovirus, e.g. autographa californica nucleopolyhedrovirus
- 2710/14121 Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2710/14122 New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2710/14123 Virus like particles [VLP]
- 2710/14131 Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2710/14132 Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2710/14133 Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2710/14134 Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2710/14141 Use of virus, viral particle or viral elements as a vector
- 2710/14142 virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2710/14143 viral genome or elements thereof as genetic vector
- 2710/14144 Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2710/14145 Special targeting system for viral vectors
- 2710/14151 Methods of production or purification of viral material
- 2710/14152 relating to complementing cells and packaging systems for producing virus or viral particles
- 2710/14161 Methods of inactivation or attenuation
- 2710/14162 by genetic engineering
- 2710/14163 by chemical treatment
- 2710/14164 by serial passage
- 2710/14171 Demonstrated in vivo effect
- 2710/14188 For redistribution
- 2710/16011 . . Herpesviridae
- 2710/16021 . . . Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2710/16022 . . . New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2710/16023 . . . Virus like particles [VLP]
- 2710/16031 . . . Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2710/16032 . . . Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2710/16033 . . . Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2710/16034 . . . Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2710/16041 . . . Use of virus, viral particle or viral elements as a vector
- 2710/16042 virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2710/16043 viral genome or elements thereof as genetic vector
- 2710/16044 Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2710/16045 Special targeting system for viral vectors
- 2710/16051 . . . Methods of production or purification of viral material
- 2710/16052 relating to complementing cells and packaging systems for producing virus or viral particles
- 2710/16061 . . . Methods of inactivation or attenuation
- 2710/16062 by genetic engineering
- 2710/16063 by chemical treatment
- 2710/16064 by serial passage
- 2710/16071 . . . Demonstrated in vivo effect
- 2710/16088 . . . for redistribution
- 2710/16111 . . . Cytomegalovirus, e.g. human herpesvirus 5
- 2710/16121 Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2710/16122 New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2710/16123 Virus like particles [VLP]
- 2710/16131 Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2710/16132 Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2710/16133 Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2710/16134 Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2710/16141 Use of virus, viral particle or viral elements as a vector
- 2710/16142 virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2710/16143 viral genome or elements thereof as genetic vector
- 2710/16144 Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2710/16145 Special targeting system for viral vectors
- 2710/16151 Methods of production or purification of viral material
- 2710/16152 relating to complementing cells and packaging systems for producing virus or viral particles
- 2710/16161 Methods of inactivation or attenuation
- 2710/16162 by genetic engineering
- 2710/16163 by chemical treatment
- 2710/16164 by serial passage
- 2710/16171 Demonstrated in vivo effect
- 2710/16188 for redistribution
- 2710/16211 . . . Lymphocryptovirus, e.g. human herpesvirus 4, Epstein-Barr Virus
- 2710/16221 Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2710/16222 New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2710/16223 Virus like particles [VLP]

- 2710/16231 Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2710/16232 Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2710/16233 Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2710/16234 Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2710/16241 Use of virus, viral particle or viral elements as a vector
- 2710/16242 virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2710/16243 viral genome or elements thereof as genetic vector
- 2710/16244 Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2710/16245 Special targeting system for viral vectors
- 2710/16251 Methods of production or purification of viral material
- 2710/16252 relating to complementing cells and packaging systems for producing virus or viral particles
- 2710/16261 Methods of inactivation or attenuation
- 2710/16262 by genetic engineering
- 2710/16263 by chemical treatment
- 2710/16264 by serial passage
- 2710/16271 Demonstrated *in vivo* effect
- 2710/16288 for redistribution
- 2710/16311 Mardivirus, e.g. Gallid herpesvirus 2, Marek-like viruses, turkey HV
- 2710/16321 Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2710/16322 New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2710/16323 Virus like particles [VLP]
- 2710/16331 Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2710/16332 Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2710/16333 Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2710/16334 Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2710/16341 Use of virus, viral particle or viral elements as a vector
- 2710/16342 virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2710/16343 viral genome or elements thereof as genetic vector
- 2710/16344 Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2710/16345 Special targeting system for viral vectors
- 2710/16351 Methods of production or purification of viral material
- 2710/16352 relating to complementin g cells and packaging systems for producing virus or viral particles
- 2710/16361 Methods of inactivation or attenuation
- 2710/16362 by genetic engineering
- 2710/16363 by chemical treatment
- 2710/16364 by serial passage
- 2710/16371 Demonstrated *in vivo* effect
- 2710/16388 for redistribution
- 2710/16411 Rhadinovirus, e.g. human herpesvirus 8
- 2710/16421 Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2710/16422 New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2710/16423 Virus like particles [VLP]
- 2710/16431 Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2710/16432 Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2710/16433 Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2710/16434 Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2710/16441 Use of virus, viral particle or viral elements as a vector
- 2710/16442 virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2710/16443 viral genome or elements thereof as genetic vector
- 2710/16444 Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2710/16445 Special targeting system for viral vectors
- 2710/16451 Methods of production or purification of viral material
- 2710/16452 relating to complementing cells and packaging systems for producing virus or viral particles
- 2710/16461 Methods of inactivation or attenuation
- 2710/16462 by genetic engineering
- 2710/16463 by chemical treatment
- 2710/16464 by serial passage
- 2710/16471 Demonstrated *in vivo* effect
- 2710/16488 for redistribution
- 2710/16511 Roseolovirus, e.g. human herpesvirus 6, 7
- 2710/16521 Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2710/16522 New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2710/16523 Virus like particles [VLP]
- 2710/16531 Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2710/16532 Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2710/16533 Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2710/16534 Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral
- 2710/16541 Use of virus, viral particle or viral elements as a vector

- 2710/16542 virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2710/16543 viral genome or elements thereof as genetic vector
- 2710/16544 Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2710/16545 Special targeting system for viral vectors
- 2710/16551 Methods of production or purification of viral material
- 2710/16552 relating to complementing cells and packaging systems for producing virus or viral particles
- 2710/16561 Methods of inactivation or attenuation
- 2710/16562 by genetic engineering
- 2710/16563 by chemical treatment
- 2710/16564 by serial passage
- 2710/16571 Demonstrated in vivo effect
- 2710/16588 for redistribution
- 2710/16611 Simplexvirus, e.g. human herpesvirus 1, 2
- 2710/16621 Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2710/16622 New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2710/16623 Virus like particles [VLP]
- 2710/16631 Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2710/16632 Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2710/16633 Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2710/16634 Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2710/16641 Use of virus, viral particle or viral elements as a vector
- 2710/16642 virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2710/16643 viral genome or elements thereof as genetic vector
- 2710/16644 Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2710/16645 Special targeting system for viral vectors
- 2710/16651 Methods of production or purification of viral material
- 2710/16652 relating to complementing cells and packaging systems for producing virus or viral particles
- 2710/16661 Methods of inactivation or attenuation
- 2710/16662 by genetic engineering
- 2710/16663 by chemical treatment
- 2710/16664 by serial passage
- 2710/16671 Demonstrated in vivo effect
- 2710/16688 for redistribution
- 2710/16711 Varicellovirus, e.g. human herpesvirus 3, Varicella Zoster, pseudorabies
- 2710/16721 Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2710/16722 New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2710/16723 Virus like particles [VLP]
- 2710/16731 Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2710/16732 Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2710/16733 Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2710/16734 Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2710/16741 Use of virus, viral particle or viral elements as a vector
- 2710/16742 virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2710/16743 viral genome or elements thereof as genetic vector
- 2710/16744 Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2710/16745 Special targeting system for viral vectors
- 2710/16751 Methods of production or purification of viral material
- 2710/16752 relating to complementing cells and packaging systems for producing virus or viral particles
- 2710/16761 Methods of inactivation or attenuation
- 2710/16762 by genetic engineering
- 2710/16763 by chemical treatment
- 2710/16764 by serial passage
- 2710/16771 Demonstrated in vivo effect
- 2710/16788 for redistribution
- 2710/18011 Nimaviridae
- 2710/18021 Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2710/18022 New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2710/18023 Virus like particles [VLP]
- 2710/18031 Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2710/18032 Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2710/18033 Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2710/18034 Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2710/18041 Use of virus, viral particle or viral elements as a vector
- 2710/18042 virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2710/18043 viral genome or elements thereof as genetic vector
- 2710/18044 Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2710/18045 Special targeting system for viral vectors
- 2710/18051 Methods of production or purification of viral material
- 2710/18052 relating to complementing cells and packaging systems for producing virus or viral particles

- 2710/18061 . . . Methods of inactivation or attenuation
- 2710/18062 by genetic engineering
- 2710/18063 by chemical treatment
- 2710/18064 by serial passage
- 2710/18071 . . . Demonstrated in vivo effect
- 2710/18088 . . . for redistribution
- 2710/20011 . . Papillomaviridae
- 2710/20021 . . . Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2710/20022 . . . New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2710/20023 . . . Virus like particles [VLP]
- 2710/20031 . . . Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2710/20032 . . . Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2710/20033 . . . Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2710/20034 . . . Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2710/20041 . . . Use of virus, viral particle or viral elements as a vector
- 2710/20042 virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2710/20043 viral genome or elements thereof as genetic vector
- 2710/20044 Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2710/20045 Special targeting system for viral vectors
- 2710/20051 . . . Methods of production or purification of viral material
- 2710/20052 relating to complementing cells and packaging systems for producing virus or viral particles
- 2710/20061 . . . Methods of inactivation or attenuation
- 2710/20062 by genetic engineering
- 2710/20063 by chemical treatment
- 2710/20064 by serial passage
- 2710/20071 . . . Demonstrated in vivo effect
- 2710/20088 . . . for redistribution
- 2710/22011 . . Polyomaviridae, e.g. polyoma, SV40, JC
- 2710/22021 . . . Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2710/22022 . . . New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2710/22023 . . . Virus like particles [VLP]
- 2710/22031 . . . Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2710/22032 . . . Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2710/22033 . . . Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2710/22034 . . . Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2710/22041 . . . Use of virus, viral particle or viral elements as a vector
- 2710/22042 virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2710/22043 viral genome or elements thereof as genetic vector
- 2710/22044 Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2710/22045 Special targeting system for viral vectors
- 2710/22051 . . . Methods of production or purification of viral material
- 2710/22052 relating to complementing cells and packaging systems for producing virus or viral particles
- 2710/22061 . . . Methods of inactivation or attenuation
- 2710/22062 by genetic engineering
- 2710/22063 by chemical treatment
- 2710/22064 by serial passage
- 2710/22071 . . . Demonstrated in vivo effect
- 2710/22088 . . . for redistribution
- 2710/24011 . . Poxviridae
- 2710/24021 . . . Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2710/24022 . . . New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2710/24023 . . . Virus like particles [VLP]
- 2710/24031 . . . Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2710/24032 . . . Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2710/24033 . . . Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2710/24034 . . . Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2710/24041 . . . Use of virus, viral particle or viral elements as a vector
- 2710/24042 virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2710/24043 viral genome or elements thereof as genetic vector
- 2710/24044 Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2710/24045 Special targeting system for viral vectors
- 2710/24051 . . . Methods of production or purification of viral material
- 2710/24052 relating to complementing cells and packaging systems for producing virus or viral particles
- 2710/24061 . . . Methods of inactivation or attenuation
- 2710/24062 by genetic engineering
- 2710/24063 by chemical treatment
- 2710/24064 by serial passage
- 2710/24071 . . . Demonstrated in vivo effect
- 2710/24088 . . . for redistribution
- 2710/24111 . . . Orthopoxvirus, e.g. vaccinia virus, variola
- 2710/24121 Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2710/24122 New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2710/24123 Virus like particles [VLP]

- 2710/24131 Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2710/24132 Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2710/24133 Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2710/24134 Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2710/24141 Use of virus, viral particle or viral elements as a vector
- 2710/24142 virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2710/24143 viral genome or elements thereof as genetic vector
- 2710/24144 Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2710/24145 Special targeting system for viral vectors
- 2710/24151 Methods of production or purification of viral material
- 2710/24152 relating to complementing cells and packaging systems for producing virus or viral particles
- 2710/24161 Methods of inactivation or attenuation
- 2710/24162 by genetic engineering
- 2710/24163 by chemical treatment
- 2710/24164 by serial passage
- 2710/24171 Demonstrated *in vivo* effect
- 2710/24188 for redistribution
- 2710/24211 . . . Parapoxvirus, e.g. Orf virus
- 2710/24221 Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2710/24222 New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2710/24223 Virus like particles [VLP]
- 2710/24231 Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2710/24232 Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2710/24233 Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2710/24234 Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2710/24241 Use of virus, viral particle or viral elements as a vector
- 2710/24242 virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2710/24243 viral genome or elements thereof as genetic vector
- 2710/24244 Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2710/24245 Special targeting system for viral vectors
- 2710/24251 Methods of production or purification of viral material
- 2710/24252 relating to complementing cells and packaging systems for producing virus or viral particles
- 2710/24261 Methods of inactivation or attenuation
- 2710/24262 by genetic engineering
- 2710/24263 by chemical treatment
- 2710/24264 by serial passage
- 2710/24271 Demonstrated *in vivo* effect
- 2710/24288 for redistribution
- 2720/00** **dsRNA viruses**
- 2720/00011 . Details
- 2720/00021 . . Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2720/00022 . . New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2720/00023 . . Virus like particles [VLP]
- 2720/00031 . . Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2720/00032 . . Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2720/00033 . . Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2720/00034 . . Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2720/00041 . . Use of virus, viral particle or viral elements as a vector
- 2720/00042 . . . virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2720/00043 . . . viral genome or elements thereof as genetic vector
- 2720/00044 . . . Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2720/00045 . . . Special targeting system for viral vectors
- 2720/00051 . . Methods of production or purification of viral material
- 2720/00052 . . . relating to complementing cells and packaging systems for producing virus or viral particles
- 2720/00061 . . Methods of inactivation or attenuation
- 2720/00062 . . . by genetic engineering
- 2720/00063 . . . by chemical treatment
- 2720/00064 . . . by serial passage
- 2720/00071 . . Demonstrated *in vivo* effect
- 2720/00088 . . for redistribution
- 2720/10011 . . Birnaviridae
- 2720/10021 . . . Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2720/10022 . . . New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2720/10023 . . . Virus like particles [VLP]
- 2720/10031 . . . Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2720/10032 . . . Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2720/10033 . . . Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2720/10034 . . . Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2720/10041 . . . Use of virus, viral particle or viral elements as a vector

- 2720/10042 virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2720/10043 viral genome or elements thereof as genetic vector
- 2720/10044 Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2720/10045 Special targeting system for viral vectors
- 2720/10051 Methods of production or purification of viral material
- 2720/10052 relating to complementing cells and packaging systems for producing virus or viral particles
- 2720/10061 Methods of inactivation or attenuation
- 2720/10062 by genetic engineering
- 2720/10063 by chemical treatment
- 2720/10064 by serial passage
- 2720/10071 Demonstrated in vivo effect
- 2720/10088 for redistribution
- 2720/12011 Reoviridae
- 2720/12021 Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2720/12022 New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2720/12023 Virus like particles [VLP]
- 2720/12031 Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2720/12032 Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2720/12033 Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2720/12034 Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2720/12041 Use of virus, viral particle or viral elements as a vector
- 2720/12042 virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2720/12043 viral genome or elements thereof as genetic vector
- 2720/12044 Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2720/12045 Special targeting system for viral vectors
- 2720/12051 Methods of production or purification of viral material
- 2720/12052 relating to complementing cells and packaging systems for producing virus or viral particles
- 2720/12061 Methods of inactivation or attenuation
- 2720/12062 by genetic engineering
- 2720/12063 by chemical treatment
- 2720/12064 by serial passage
- 2720/12071 Demonstrated in vivo effect
- 2720/12088 for redistribution
- 2720/12111 Orbivirus, e.g. bluetongue virus
- 2720/12121 Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2720/12122 New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2720/12123 Virus like particles [VLP]
- 2720/12131 Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2720/12132 Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2720/12133 Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2720/12134 Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2720/12141 Use of virus, viral particle or viral elements as a vector
- 2720/12142 virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2720/12143 viral genome or elements thereof as genetic vector
- 2720/12144 Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2720/12145 Special targeting system for viral vectors
- 2720/12151 Methods of production or purification of viral material
- 2720/12152 relating to complementing cells and packaging systems for producing virus or viral particles
- 2720/12161 Methods of inactivation or attenuation
- 2720/12162 by genetic engineering
- 2720/12163 by chemical treatment
- 2720/12164 by serial passage
- 2720/12171 Demonstrated in vivo effect
- 2720/12188 for redistribution
- 2720/12211 Orthoreovirus, e.g. mammalian orthoreovirus
- 2720/12221 Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2720/12222 New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2720/12223 Virus like particles [VLP]
- 2720/12231 Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2720/12232 Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2720/12233 Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2720/12234 Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2720/12241 Use of virus, viral particle or viral elements as a vector
- 2720/12242 virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2720/12243 viral genome or elements thereof as genetic vector
- 2720/12244 Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2720/12245 Special targeting system for viral vectors
- 2720/12251 Methods of production or purification of viral material
- 2720/12252 relating to complementing cells and packaging systems for producing virus or viral particles
- 2720/12261 Methods of inactivation or attenuation

- 2720/12262 by genetic engineering
- 2720/12263 by chemical treatment
- 2720/12264 by serial passage
- 2720/12271 Demonstrated *in vivo* effect
- 2720/12288 for redistribution
- 2720/12311 . . . Rotavirus, e.g. rotavirus A
- 2720/12321 Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2720/12322 New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2720/12323 Virus like particles [VLP]
- 2720/12331 Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2720/12332 Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2720/12333 Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2720/12334 Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2720/12341 Use of virus, viral particle or viral elements as a vector
- 2720/12342 virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2720/12343 viral genome or elements thereof as genetic vector
- 2720/12344 Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2720/12345 Special targeting system for viral vectors
- 2720/12351 Methods of production or purification of viral material
- 2720/12352 relating to complementing cells and packaging systems for producing virus or viral particles
- 2720/12361 Methods of inactivation or attenuation
- 2720/12362 by genetic engineering
- 2720/12363 by chemical treatment
- 2720/12364 by serial passage
- 2720/12371 Demonstrated *in vivo* effect
- 2720/12388 for redistribution
- 2730/00** **Reverse transcribing DNA viruses**
- 2730/00011 . Details
- 2730/00021 . . Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2730/00022 . . New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2730/00023 . . Virus like particles [VLP]
- 2730/00031 . . Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2730/00032 . . Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2730/00033 . . Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2730/00034 . . Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2730/00041 . . Use of virus, viral particle or viral elements as a vector
- 2730/00042 . . . virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2730/00043 . . . viral genome or elements thereof as genetic vector
- 2730/00044 . . . Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2730/00045 . . . Special targeting system for viral vectors
- 2730/00051 . . . Methods of production or purification of viral material
- 2730/00052 relating to complementing cells and packaging systems for producing virus or viral particles
- 2730/00061 . . . Methods of inactivation or attenuation
- 2730/00062 by genetic engineering
- 2730/00063 by chemical treatment
- 2730/00064 by serial passage
- 2730/00071 . . . Demonstrated *in vivo* effect
- 2730/00088 . . . for redistribution
- 2730/10011 . . . Hepadnaviridae
- 2730/10021 Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2730/10022 New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2730/10023 Virus like particles [VLP]
- 2730/10031 Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2730/10032 Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2730/10033 Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2730/10034 Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2730/10041 Use of virus, viral particle or viral elements as a vector
- 2730/10042 virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2730/10043 viral genome or elements thereof as genetic vector
- 2730/10044 Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2730/10045 Special targeting system for viral vectors
- 2730/10051 Methods of production or purification of viral material
- 2730/10052 relating to complementing cells and packaging systems for producing virus or viral particles
- 2730/10061 Methods of inactivation or attenuation
- 2730/10062 by genetic engineering
- 2730/10063 by chemical treatment
- 2730/10064 by serial passage
- 2730/10071 Demonstrated *in vivo* effect
- 2730/10088 for redistribution
- 2730/10111 Orthohepadnavirus, e.g. hepatitis B virus
- 2730/10121 Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2730/10122 New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2730/10123 Virus like particles [VLP]

- 2730/10131 Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2730/10132 Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2730/10133 Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2730/10134 Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2730/10141 Use of virus, viral particle or viral elements as a vector
- 2730/10142 virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2730/10143 viral genome or elements thereof as genetic vector
- 2730/10144 Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2730/10145 Special targeting system for viral vectors
- 2730/10151 Methods of production or purification of viral material
- 2730/10152 relating to complementing cells and packaging systems for producing virus or viral particles
- 2730/10161 Methods of inactivation or attenuation
- 2730/10162 by genetic engineering
- 2730/10163 by chemical treatment
- 2730/10164 by serial passage
- 2730/10171 Demonstrated *in vivo* effect
- 2730/10188 for redistribution
- 2740/00** **Reverse transcribing RNA viruses**
- 2740/00011 . Details
- 2740/00021 . . Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2740/00022 . . New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2740/00023 . . Virus like particles [VLP]
- 2740/00031 . . Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2740/00032 . . Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2740/00033 . . Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2740/00034 . . Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2740/00041 . . Use of virus, viral particle or viral elements as a vector
- 2740/00042 . . . virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2740/00043 . . . viral genome or elements thereof as genetic vector
- 2740/00044 . . . Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2740/00045 . . . Special targeting system for viral vectors
- 2740/00051 . . Methods of production or purification of viral material
- 2740/00052 . . . relating to complementing cells and packaging systems for producing virus or viral particles
- 2740/00061 . . Methods of inactivation or attenuation
- 2740/00062 . . . by genetic engineering
- 2740/00063 . . . by chemical treatment
- 2740/00064 . . . by serial passage
- 2740/00071 . . Demonstrated *in vivo* effect
- 2740/00088 . . for redistribution
- 2740/10011 . . Retroviridae
- 2740/10021 . . . Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2740/10022 . . . New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2740/10023 . . . Virus like particles [VLP]
- 2740/10031 . . . Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2740/10032 . . . Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2740/10033 . . . Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2740/10034 . . . Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2740/10041 . . . Use of virus, viral particle or viral elements as a vector
- 2740/10042 virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2740/10043 viral genome or elements thereof as genetic vector
- 2740/10044 Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2740/10045 Special targeting system for viral vectors
- 2740/10051 . . . Methods of production or purification of viral material
- 2740/10052 relating to complementing cells and packaging systems for producing virus or viral particles
- 2740/10061 . . . Methods of inactivation or attenuation
- 2740/10062 by genetic engineering
- 2740/10063 by chemical treatment
- 2740/10064 by serial passage
- 2740/10071 . . . Demonstrated *in vivo* effect
- 2740/10088 . . . for redistribution
- 2740/11011 . . . Alpharetrovirus, e.g. avian leucosis virus
- 2740/11021 Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2740/11022 New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2740/11023 Virus like particles [VLP]
- 2740/11031 Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2740/11032 Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2740/11033 Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2740/11034 Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2740/11041 Use of virus, viral particle or viral elements as a vector

- 2740/11042 virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2740/11043 viral genome or elements thereof as genetic vector
- 2740/11044 Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2740/11045 Special targeting system for viral vectors
- 2740/11051 Methods of production or purification of viral material
- 2740/11052 relating to complementing cells and packaging systems for producing virus or viral particles
- 2740/11061 Methods of inactivation or attenuation
- 2740/11062 by genetic engineering
- 2740/11063 by chemical treatment
- 2740/11064 by serial passage
- 2740/11071 Demonstrated in vivo effect
- 2740/11088 for redistribution
- 2740/12011 Betaretrovirus, e.g. mouse mammary tumour virus
- 2740/12021 Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2740/12022 New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2740/12023 Virus like particles [VLP]
- 2740/12031 Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2740/12032 Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2740/12033 Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2740/12034 Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2740/12041 Use of virus, viral particle or viral elements as a vector
- 2740/12042 virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2740/12043 viral genome or elements thereof as genetic vector
- 2740/12044 Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2740/12045 Special targeting system for viral vectors
- 2740/12051 Methods of production or purification of viral material
- 2740/12052 relating to complementing cells and packaging systems for producing virus or viral particles
- 2740/12061 Methods of inactivation or attenuation
- 2740/12062 by genetic engineering
- 2740/12063 by chemical treatment
- 2740/12064 by serial passage
- 2740/12071 Demonstrated in vivo effect
- 2740/12088 for redistribution
- 2740/13011 Gammaretrovirus, e.g. murine leukaemia virus
- 2740/13021 Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2740/13022 New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2740/13023 Virus like particles [VLP]
- 2740/13031 Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2740/13032 Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2740/13033 Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2740/13034 Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2740/13041 Use of virus, viral particle or viral elements as a vector
- 2740/13042 virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2740/13043 viral genome or elements thereof as genetic vector
- 2740/13044 Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2740/13045 Special targeting system for viral vectors
- 2740/13051 Methods of production or purification of viral material
- 2740/13052 relating to complementing cells and packaging systems for producing virus or viral particles
- 2740/13061 Methods of inactivation or attenuation
- 2740/13062 by genetic engineering
- 2740/13063 by chemical treatment
- 2740/13064 by serial passage
- 2740/13071 Demonstrated in vivo effect
- 2740/13088 for redistribution
- 2740/14011 Deltaretrovirus, e.g. bovine leukaemia virus
- 2740/14021 Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2740/14022 New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2740/14023 Virus like particles [VLP]
- 2740/14031 Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2740/14032 Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2740/14033 Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2740/14034 Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2740/14041 Use of virus, viral particle or viral elements as a vector
- 2740/14042 virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2740/14043 viral genome or elements thereof as genetic vector
- 2740/14044 Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2740/14045 Special targeting system for viral vectors
- 2740/14051 Methods of production or purification of viral material
- 2740/14052 relating to complementing cells and packaging systems for producing virus or viral particles

- 2740/14061 Methods of inactivation or attenuation
- 2740/14062 by genetic engineering
- 2740/14063 by chemical treatment
- 2740/14064 by serial passage
- 2740/14071 Demonstrated *in vivo* effect
- 2740/14088 for redistribution
- 2740/15011 Lentivirus, not HIV, e.g. FIV, SIV
- 2740/15021 Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2740/15022 New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2740/15023 Virus like particles [VLP]
- 2740/15031 Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2740/15032 Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2740/15033 Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2740/15034 Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2740/15041 Use of virus, viral particle or viral elements as a vector
- 2740/15042 virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2740/15043 viral genome or elements thereof as genetic vector
- 2740/15044 Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2740/15045 Special targeting system for viral vectors
- 2740/15051 Methods of production or purification of viral material
- 2740/15052 relating to complementing cells and packaging systems for producing virus or viral particles
- 2740/15061 Methods of inactivation or attenuation
- 2740/15062 by genetic engineering
- 2740/15063 by chemical treatment
- 2740/15064 by serial passage
- 2740/15071 Demonstrated *in vivo* effect
- 2740/15088 for redistribution
- 2740/16011 Human Immunodeficiency Virus, HIV
- 2740/16021 Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2740/16022 New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2740/16023 Virus like particles [VLP]
- 2740/16031 Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2740/16032 Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2740/16033 Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2740/16034 Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2740/16041 Use of virus, viral particle or viral elements as a vector
- 2740/16042 virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2740/16043 viral genome or elements thereof as genetic vector
- 2740/16044 Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2740/16045 Special targeting system for viral vectors
- 2740/16051 Methods of production or purification of viral material
- 2740/16052 relating to complementing cells and packaging systems for producing virus or viral particles
- 2740/16061 Methods of inactivation or attenuation
- 2740/16062 by genetic engineering
- 2740/16063 by chemical treatment
- 2740/16064 by serial passage
- 2740/16071 Demonstrated *in vivo* effect
- 2740/16088 for redistribution
- 2740/16111 concerning HIV env
- 2740/16122 New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2740/16134 Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2740/16171 Demonstrated *in vivo* effect
- 2740/16188 for redistribution
- 2740/16211 concerning HIV gagpol
- 2740/16222 New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2740/16234 Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2740/16271 Demonstrated *in vivo* effect
- 2740/16288 for redistribution
- 2740/16311 concerning HIV regulatory proteins
- 2740/16322 New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2740/16334 Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2740/16371 Demonstrated *in vivo* effect
- 2740/16388 for redistribution
- 2740/17011 Spumavirus, e.g. chimpanzee foamy virus
- 2740/17021 Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2740/17022 New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2740/17023 Virus like particles [VLP]
- 2740/17031 Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2740/17032 Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2740/17033 Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2740/17034 Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

- 2740/17041 Use of virus, viral particle or viral elements as a vector
- 2740/17042 virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2740/17043 viral genome or elements thereof as genetic vector
- 2740/17044 Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2740/17045 Special targeting system for viral vectors
- 2740/17051 Methods of production or purification of viral material
- 2740/17052 relating to complementing cells and packaging systems for producing virus or viral particles
- 2740/17061 Methods of inactivation or attenuation
- 2740/17062 by genetic engineering
- 2740/17063 by chemical treatment
- 2740/17064 by serial passage
- 2740/17071 Demonstrated *in vivo* effect
- 2740/17088 for redistribution
- 2750/00** **ssDNA viruses**
- 2750/00011 . . Details
- 2750/00021 . . Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2750/00022 . . New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2750/00023 . . Virus like particles [VLP]
- 2750/00031 . . Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2750/00032 . . Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2750/00033 . . Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2750/00034 . . Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2750/00041 . . Use of virus, viral particle or viral elements as a vector
- 2750/00042 . . . virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2750/00043 . . . viral genome or elements thereof as genetic vector
- 2750/00044 . . . Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2750/00045 . . . Special targeting system for viral vectors
- 2750/00051 . . . Methods of production or purification of viral material
- 2750/00052 . . . relating to complementing cells and packaging systems for producing virus or viral particles
- 2750/00061 . . . Methods of inactivation or attenuation
- 2750/00062 . . . by genetic engineering
- 2750/00063 . . . by chemical treatment
- 2750/00064 . . . by serial passage
- 2750/00071 . . . Demonstrated *in vivo* effect
- 2750/00088 . . . for redistribution
- 2750/10011 . . . Circoviridae
- 2750/10021 . . . Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2750/10022 . . . New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2750/10023 . . . Virus like particles [VLP]
- 2750/10031 . . . Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2750/10032 . . . Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2750/10033 . . . Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2750/10034 . . . Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2750/10041 . . . Use of virus, viral particle or viral elements as a vector
- 2750/10042 virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2750/10043 viral genome or elements thereof as genetic vector
- 2750/10044 Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2750/10045 Special targeting system for viral vectors
- 2750/10051 Methods of production or purification of viral material
- 2750/10052 relating to complementing cells and packaging systems for producing virus or viral particles
- 2750/10061 Methods of inactivation or attenuation
- 2750/10062 by genetic engineering
- 2750/10063 by chemical treatment
- 2750/10064 by serial passage
- 2750/10071 Demonstrated *in vivo* effect
- 2750/10088 for redistribution
- 2750/12011 . . . Geminiviridae
- 2750/12021 . . . Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2750/12022 . . . New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2750/12023 . . . Virus like particles [VLP]
- 2750/12031 . . . Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2750/12032 . . . Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2750/12033 . . . Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2750/12034 . . . Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2750/12041 . . . Use of virus, viral particle or viral elements as a vector
- 2750/12042 virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2750/12043 viral genome or elements thereof as genetic vector
- 2750/12044 Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2750/12045 Special targeting system for viral vectors
- 2750/12051 Methods of production or purification of viral material

- 2750/12052 . . . relating to complementing cells and packaging systems for producing virus or viral particles
- 2750/12061 . . . Methods of inactivation or attenuation
- 2750/12062 . . . by genetic engineering
- 2750/12063 . . . by chemical treatment
- 2750/12064 . . . by serial passage
- 2750/12071 . . . Demonstrated in vivo effect
- 2750/12088 . . . for redistribution
- 2750/14011 . . Parvoviridae
- 2750/14021 . . . Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2750/14022 . . . New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2750/14023 . . . Virus like particles [VLP]
- 2750/14031 . . . Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2750/14032 . . . Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2750/14033 . . . Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2750/14034 . . . Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2750/14041 . . . Use of virus, viral particle or viral elements as a vector
- 2750/14042 . . . virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2750/14043 . . . viral genome or elements thereof as genetic vector
- 2750/14044 . . . Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2750/14045 . . . Special targeting system for viral vectors
- 2750/14051 . . . Methods of production or purification of viral material
- 2750/14052 . . . relating to complementing cells and packaging systems for producing virus or viral particles
- 2750/14061 . . . Methods of inactivation or attenuation
- 2750/14062 . . . by genetic engineering
- 2750/14063 . . . by chemical treatment
- 2750/14064 . . . by serial passage
- 2750/14071 . . . Demonstrated in vivo effect
- 2750/14088 . . . for redistribution
- 2750/14111 . . . Dependovirus, e.g. adenoassociated viruses
- 2750/14121 . . . Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2750/14122 . . . New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2750/14123 . . . Virus like particles [VLP]
- 2750/14131 . . . Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2750/14132 . . . Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2750/14133 . . . Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2750/14134 . . . Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2750/14141 . . . Use of virus, viral particle or viral elements as a vector
- 2750/14142 . . . virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2750/14143 . . . viral genome or elements thereof as genetic vector
- 2750/14144 . . . Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2750/14145 . . . Special targeting system for viral vectors
- 2750/14151 . . . Methods of production or purification of viral material
- 2750/14152 . . . relating to complementing cells and packaging systems for producing virus or viral particles
- 2750/14161 . . . Methods of inactivation or attenuation
- 2750/14162 . . . by genetic engineering
- 2750/14163 . . . by chemical treatment
- 2750/14164 . . . by serial passage
- 2750/14171 . . . Demonstrated in vivo effect
- 2750/14188 . . . for redistribution
- 2750/14211 . . . Erythrovirus, e.g. B19 virus
- 2750/14221 . . . Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2750/14222 . . . New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2750/14223 . . . Virus like particles [VLP]
- 2750/14231 . . . Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2750/14232 . . . Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2750/14233 . . . Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2750/14234 . . . Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2750/14241 . . . Use of virus, viral particle or viral elements as a vector
- 2750/14242 . . . virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2750/14243 . . . viral genome or elements thereof as genetic vector
- 2750/14244 . . . Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2750/14245 . . . Special targeting system for viral vectors
- 2750/14251 . . . Methods of production or purification of viral material
- 2750/14252 . . . relating to complementing cells and packaging systems for producing virus or viral particles
- 2750/14261 . . . Methods of inactivation or attenuation
- 2750/14262 . . . by genetic engineering
- 2750/14263 . . . by chemical treatment
- 2750/14264 . . . by serial passage
- 2750/14271 . . . Demonstrated in vivo effect
- 2750/14288 . . . for redistribution
- 2750/14311 . . . Parvovirus, e.g. minute virus of mice
- 2750/14321 . . . Viruses as such, e.g. new isolates, mutants or their genomic sequences

- 2750/14322 New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2750/14323 Virus like particles [VLP]
- 2750/14331 Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2750/14332 Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2750/14333 Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2750/14334 Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2750/14341 Use of virus, viral particle or viral elements as a vector
- 2750/14342 virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2750/14343 viral genome or elements thereof as genetic vector
- 2750/14344 Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2750/14345 Special targeting system for viral vectors
- 2750/14351 Methods of production or purification of viral material
- 2750/14352 relating to complementing cells and packaging systems for producing virus or viral particles
- 2750/14361 Methods of inactivation or attenuation
- 2750/14362 by genetic engineering
- 2750/14363 by chemical treatment
- 2750/14364 by serial passage
- 2750/14371 Demonstrated *in vivo* effect
- 2750/14388 for redistribution
- 2760/00** **ssRNA viruses negative-sense**
- 2760/00011 . Details
- 2760/00021 . . Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2760/00022 . . New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2760/00023 . . Virus like particles [VLP]
- 2760/00031 . . Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2760/00032 . . Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2760/00033 . . Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2760/00034 . . Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2760/00041 . . Use of virus, viral particle or viral elements as a vector
- 2760/00042 . . . virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2760/00043 . . . viral genome or elements thereof as genetic vector
- 2760/00044 . . . Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2760/00045 . . . Special targeting system for viral vectors
- 2760/00051 . . Methods of production or purification of viral material
- 2760/00052 . . . relating to complementing cells and packaging systems for producing virus or viral particles
- 2760/00061 . . Methods of inactivation or attenuation
- 2760/00062 . . . by genetic engineering
- 2760/00063 . . . by chemical treatment
- 2760/00064 . . . by serial passage
- 2760/00071 . . Demonstrated *in vivo* effect
- 2760/00088 . . for redistribution
- 2760/10011 . . Arenaviridae
- 2760/10021 . . . Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2760/10022 . . . New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2760/10023 . . . Virus like particles [VLP]
- 2760/10031 . . . Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2760/10032 . . . Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2760/10033 . . . Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2760/10034 . . . Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2760/10041 . . . Use of virus, viral particle or viral elements as a vector
- 2760/10042 virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2760/10043 viral genome or elements thereof as genetic vector
- 2760/10044 Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2760/10045 Special targeting system for viral vectors
- 2760/10051 . . . Methods of production or purification of viral material
- 2760/10052 relating to complementing cells and packaging systems for producing virus or viral particles
- 2760/10061 . . . Methods of inactivation or attenuation
- 2760/10062 by genetic engineering
- 2760/10063 by chemical treatment
- 2760/10064 by serial passage
- 2760/10071 . . . Demonstrated *in vivo* effect
- 2760/10088 . . . for redistribution
- 2760/10111 . . . Deltavirus, e.g. hepatitis delta virus
- 2760/10121 Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2760/10122 New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2760/10123 Virus like particles [VLP]
- 2760/10131 Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2760/10132 Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2760/10133 Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory

- 2760/10134 Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2760/10141 Use of virus, viral particle or viral elements as a vector
- 2760/10142 virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2760/10143 viral genome or elements thereof as genetic vector
- 2760/10144 Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2760/10145 Special targeting system for viral vectors
- 2760/10151 Methods of production or purification of viral material
- 2760/10152 relating to complementing cells and packaging systems for producing virus or viral particles
- 2760/10161 Methods of inactivation or attenuation
- 2760/10162 by genetic engineering
- 2760/10163 by chemical treatment
- 2760/10164 by serial passage
- 2760/10171 Demonstrated in vivo effect
- 2760/10188 for redistribution
- 2760/12011 Bunyaviridae
- 2760/12021 Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2760/12022 New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2760/12023 Virus like particles [VLP]
- 2760/12031 Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2760/12032 Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2760/12033 Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2760/12034 Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2760/12041 Use of virus, viral particle or viral elements as a vector
- 2760/12042 virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2760/12043 viral genome or elements thereof as genetic vector
- 2760/12044 Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2760/12045 Special targeting system for viral vectors
- 2760/12051 Methods of production or purification of viral material
- 2760/12052 relating to complementing cells and packaging systems for producing virus or viral particles
- 2760/12061 Methods of inactivation or attenuation
- 2760/12062 by genetic engineering
- 2760/12063 by chemical treatment
- 2760/12064 by serial passage
- 2760/12071 Demonstrated in vivo effect
- 2760/12088 for redistribution
- 2760/12111 Hantavirus, e.g. Hantaan virus
- 2760/12121 Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2760/12122 New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2760/12123 Virus like particles [VLP]
- 2760/12131 Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2760/12132 Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2760/12133 Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2760/12134 Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2760/12141 Use of virus, viral particle or viral elements as a vector
- 2760/12142 virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2760/12143 viral genome or elements thereof as genetic vector
- 2760/12144 Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2760/12145 Special targeting system for viral vectors
- 2760/12151 Methods of production or purification of viral material
- 2760/12152 relating to complementing cells and packaging systems for producing virus or viral particles
- 2760/12161 Methods of inactivation or attenuation
- 2760/12162 by genetic engineering
- 2760/12163 by chemical treatment
- 2760/12164 by serial passage
- 2760/12171 Demonstrated in vivo effect
- 2760/12188 for redistribution
- 2760/12211 Phlebovirus, e.g. Rift Valley fever virus
- 2760/12221 Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2760/12222 New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2760/12223 Virus like particles [VLP]
- 2760/12231 Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2760/12232 Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2760/12233 Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2760/12234 Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2760/12241 Use of virus, viral particle or viral elements as a vector
- 2760/12242 virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2760/12243 viral genome or elements thereof as genetic vector
- 2760/12244 Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2760/12245 Special targeting system for viral vectors

- 2760/12251 Methods of production or purification of viral material
- 2760/12252 relating to complementing cells and packaging systems for producing virus or viral particles
- 2760/12261 Methods of inactivation or attenuation
- 2760/12262 by genetic engineering
- 2760/12263 by chemical treatment
- 2760/12264 by serial passage
- 2760/12271 Demonstrated in vivo effect
- 2760/12288 for redistribution
- 2760/14011 . . Filoviridae
- 2760/14021 . . . Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2760/14022 . . . New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2760/14023 . . . Virus like particles [VLP]
- 2760/14031 . . . Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2760/14032 . . . Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2760/14033 . . . Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2760/14034 . . . Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2760/14041 . . . Use of virus, viral particle or viral elements as a vector
- 2760/14042 . . . virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2760/14043 . . . viral genome or elements thereof as genetic vector
- 2760/14044 . . . Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2760/14045 . . . Special targeting system for viral vectors
- 2760/14051 . . . Methods of production or purification of viral material
- 2760/14052 . . . relating to complementing cells and packaging systems for producing virus or viral particles
- 2760/14061 . . . Methods of inactivation or attenuation
- 2760/14062 . . . by genetic engineering
- 2760/14063 . . . by chemical treatment
- 2760/14064 . . . by serial passage
- 2760/14071 . . . Demonstrated in vivo effect
- 2760/14088 . . . for redistribution
- 2760/14111 . . . Ebolavirus, e.g. Zaire ebolavirus
- 2760/14121 Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2760/14122 New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2760/14123 Virus like particles [VLP]
- 2760/14131 Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2760/14132 Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2760/14133 Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2760/14134 Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2760/14141 Use of virus, viral particle or viral elements as a vector
- 2760/14142 virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2760/14143 viral genome or elements thereof as genetic vector
- 2760/14144 Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2760/14145 Special targeting system for viral vectors
- 2760/14151 Methods of production or purification of viral material
- 2760/14152 relating to complementing cells and packaging systems for producing virus or viral particles
- 2760/14161 Methods of inactivation or attenuation
- 2760/14162 by genetic engineering
- 2760/14163 by chemical treatment
- 2760/14164 by serial passage
- 2760/14171 Demonstrated in vivo effect
- 2760/14188 for redistribution
- 2760/14211 . . . Marburgvirus, e.g. lake Victoria marburgvirus
- 2760/14221 Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2760/14222 New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2760/14223 Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2760/14231 Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2760/14232 Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2760/14233 Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2760/14234 Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2760/14241 Use of virus, viral particle or viral elements as a vector
- 2760/14242 virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2760/14243 viral genome or elements thereof as genetic vector
- 2760/14244 Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2760/14245 Special targeting system for viral vectors
- 2760/14251 Methods of production or purification of viral material
- 2760/14252 relating to complementing cells and packaging systems for producing virus or viral particles
- 2760/14261 Methods of inactivation or attenuation
- 2760/14262 by genetic engineering
- 2760/14263 by chemical treatment
- 2760/14264 by serial passage
- 2760/14271 Demonstrated in vivo effect
- 2760/14288 for redistribution
- 2760/16011 . . Orthomyxoviridae

- 2760/16021 . . . Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2760/16022 . . . New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2760/16023 . . . Virus like particles [VLP]
- 2760/16031 . . . Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2760/16032 . . . Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2760/16033 . . . Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2760/16034 . . . Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2760/16041 . . . Use of virus, viral particle or viral elements as a vector
- 2760/16042 virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2760/16043 viral genome or elements thereof as genetic vector
- 2760/16044 Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2760/16045 Special targeting system for viral vectors
- 2760/16051 . . . Methods of production or purification of viral material
- 2760/16052 relating to complementing cells and packaging systems for producing virus or viral particles
- 2760/16061 . . . Methods of inactivation or attenuation
- 2760/16062 by genetic engineering
- 2760/16063 by chemical treatment
- 2760/16064 by serial passage
- 2760/16071 . . . Demonstrated in vivo effect
- 2760/16088 . . . for redistribution
- 2760/16111 . . . Influenzavirus A, i.e. influenza A virus
- 2760/16121 Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2760/16122 New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2760/16123 Virus like particles [VLP]
- 2760/16131 Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2760/16132 Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2760/16133 Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2760/16134 Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2760/16141 Use of virus, viral particle or viral elements as a vector
- 2760/16142 virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2760/16143 viral genome or elements thereof as genetic vector
- 2760/16144 Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2760/16145 Special targeting system for viral vectors
- 2760/16151 Methods of production or purification of viral material
- 2760/16152 relating to complementing cells and packaging systems for producing virus or viral particles
- 2760/16161 Methods of inactivation or attenuation
- 2760/16162 by genetic engineering
- 2760/16163 by chemical treatment
- 2760/16164 by serial passage
- 2760/16171 Demonstrated in vivo effect
- 2760/16188 for redistribution
- 2760/16211 . . . Influenzavirus B, i.e. influenza B virus
- 2760/16221 Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2760/16222 New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2760/16223 Virus like particles [VLP]
- 2760/16231 Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2760/16232 Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2760/16233 Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2760/16234 Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2760/16241 Use of virus, viral particle or viral elements as a vector
- 2760/16242 virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2760/16243 viral genome or elements thereof as genetic vector
- 2760/16244 Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2760/16245 Special targeting system for viral vectors
- 2760/16251 Methods of production or purification of viral material
- 2760/16252 relating to complementing cells and packaging systems for producing virus or viral particles
- 2760/16261 Methods of inactivation or attenuation
- 2760/16262 by genetic engineering
- 2760/16263 by chemical treatment
- 2760/16264 by serial passage
- 2760/16271 Demonstrated in vivo effect
- 2760/16288 for redistribution
- 2760/16311 . . . Influenzavirus C, i.e. influenza C virus
- 2760/16321 Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2760/16322 New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2760/16323 Virus like particles [VLP]
- 2760/16331 Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2760/16332 Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2760/16333 Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory

- 2760/16334 Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2760/16341 Use of virus, viral particle or viral elements as a vector
- 2760/16342 virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2760/16343 viral genome or elements thereof as genetic vector
- 2760/16344 Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2760/16345 Special targeting system for viral vectors
- 2760/16351 Methods of production or purification of viral material
- 2760/16352 relating to complementing cells and packaging systems for producing virus or viral particles
- 2760/16361 Methods of inactivation or attenuation
- 2760/16362 by genetic engineering
- 2760/16363 by chemical treatment
- 2760/16364 by serial passage
- 2760/16371 Demonstrated in vivo effect
- 2760/16388 for redistribution
- 2760/18011 . . . Paramyxoviridae
- 2760/18021 Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2760/18022 New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2760/18023 Virus like particles [VLP]
- 2760/18031 Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2760/18032 Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2760/18033 Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2760/18034 Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2760/18041 Use of virus, viral particle or viral elements as a vector
- 2760/18042 virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2760/18043 viral genome or elements thereof as genetic vector
- 2760/18044 Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2760/18045 Special targeting system for viral vectors
- 2760/18051 Methods of production or purification of viral material
- 2760/18052 relating to complementing cells and packaging systems for producing virus or viral particles
- 2760/18061 Methods of inactivation or attenuation
- 2760/18062 by genetic engineering
- 2760/18063 by chemical treatment
- 2760/18064 by serial passage
- 2760/18071 Demonstrated in vivo effect
- 2760/18088 for redistribution
- 2760/18111 Avulavirus, e.g. Newcastle disease virus
- 2760/18121 Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2760/18122 New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2760/18123 Virus like particles [VLP]
- 2760/18131 Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2760/18132 Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2760/18133 Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2760/18134 Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2760/18141 Use of virus, viral particle or viral elements as a vector
- 2760/18142 virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2760/18143 viral genome or elements thereof as genetic vector
- 2760/18144 Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2760/18145 Special targeting system for viral vectors
- 2760/18151 Methods of production or purification of viral material
- 2760/18152 relating to complementing cells and packaging systems for producing virus or viral particles
- 2760/18161 Methods of inactivation or attenuation
- 2760/18162 by genetic engineering
- 2760/18163 by chemical treatment
- 2760/18164 by serial passage
- 2760/18171 Demonstrated in vivo effect
- 2760/18188 for redistribution
- 2760/18211 Henipavirus, e.g. hendra virus
- 2760/18221 Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2760/18222 New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2760/18223 Virus like particles [VLP]
- 2760/18231 Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2760/18232 Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2760/18233 Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2760/18234 Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2760/18241 Use of virus, viral particle or viral elements as a vector
- 2760/18242 virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2760/18243 viral genome or elements thereof as genetic vector
- 2760/18244 Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2760/18245 Special targeting system for viral vectors

- 2760/18251 Methods of production or purification of viral material
- 2760/18252 relating to complementing cells and packaging systems for producing virus or viral particles
- 2760/18261 Methods of inactivation or attenuation
- 2760/18262 by genetic engineering
- 2760/18263 by chemical treatment
- 2760/18264 by serial passage
- 2760/18271 Demonstrated *in vivo* effect
- 2760/18288 for redistribution
- 2760/18311 . . . Metapneumovirus, e.g. avian pneumovirus
- 2760/18321 Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2760/18322 New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2760/18323 Virus like particles [VLP]
- 2760/18331 Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2760/18332 Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2760/18333 Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2760/18334 Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2760/18341 Use of virus, viral particle or viral elements as a vector
- 2760/18342 virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2760/18343 viral genome or elements thereof as genetic vector
- 2760/18344 Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2760/18345 Special targeting system for viral vectors
- 2760/18351 Methods of production or purification of viral material
- 2760/18352 relating to complementing cells and packaging systems for producing virus or viral particles
- 2760/18361 Methods of inactivation or attenuation
- 2760/18362 by genetic engineering
- 2760/18363 by chemical treatment
- 2760/18364 by serial passage
- 2760/18371 Demonstrated *in vivo* effect
- 2760/18388 for redistribution
- 2760/18411 . . . Morbillivirus, e.g. Measles virus, canine distemper
- 2760/18421 Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2760/18422 New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2760/18423 Virus like particles [VLP]
- 2760/18431 Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2760/18432 Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2760/18433 Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2760/18434 Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2760/18441 Use of virus, viral particle or viral elements as a vector
- 2760/18442 virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2760/18443 viral genome or elements thereof as genetic vector
- 2760/18444 Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2760/18445 Special targeting system for viral vectors
- 2760/18451 Methods of production or purification of viral material
- 2760/18452 relating to complementing cells and packaging systems for producing virus or viral particles
- 2760/18461 Methods of inactivation or attenuation
- 2760/18462 by genetic engineering
- 2760/18463 by chemical treatment
- 2760/18464 by serial passage
- 2760/18471 Demonstrated *in vivo* effect
- 2760/18488 For redistribution
- 2760/18511 . . . Pneumovirus, e.g. human respiratory syncytial virus
- 2760/18521 Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2760/18522 New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2760/18523 Virus like particles [VLP]
- 2760/18531 Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2760/18532 Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2760/18533 Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2760/18534 Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2760/18541 Use of virus, viral particle or viral elements as a vector
- 2760/18542 virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2760/18543 viral genome or elements thereof as genetic vector
- 2760/18544 Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2760/18545 Special targeting system for viral vectors
- 2760/18551 Methods of production or purification of viral material
- 2760/18552 relating to complementing cells and packaging systems for producing virus or viral particles
- 2760/18561 Methods of inactivation or attenuation
- 2760/18562 by genetic engineering
- 2760/18563 by chemical treatment
- 2760/18564 by serial passage
- 2760/18571 Demonstrated *in vivo* effect
- 2760/18588 for redistribution

- 2760/18611 Respirovirus, e.g. Bovine, human parainfluenza 1,3
- 2760/18621 Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2760/18622 New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2760/18623 Virus like particles [VLP]
- 2760/18631 Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2760/18632 Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2760/18633 Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2760/18634 Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2760/18641 Use of virus, viral particle or viral elements as a vector
- 2760/18642 virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2760/18643 viral genome or elements thereof as genetic vector
- 2760/18644 Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2760/18645 Special targeting system for viral vectors
- 2760/18651 Methods of production or purification of viral material
- 2760/18652 relating to complementing cells and packaging systems for producing virus or viral particles
- 2760/18661 Methods of inactivation or attenuation
- 2760/18662 by genetic engineering
- 2760/18663 by chemical treatment
- 2760/18664 by serial passage
- 2760/18671 Demonstrated in vivo effect
- 2760/18688 for redistribution
- 2760/18711 Rubulavirus, e.g. mumps virus, parainfluenza 2,4
- 2760/18721 Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2760/18722 New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2760/18723 Virus like particles [VLP]
- 2760/18731 Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2760/18732 Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2760/18733 Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2760/18734 Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2760/18741 Use of virus, viral particle or viral elements as a vector
- 2760/18742 virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2760/18743 viral genome or elements thereof as genetic vector
- 2760/18744 Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2760/18745 Special targeting system for viral vectors
- 2760/18751 Methods of production or purification of viral material
- 2760/18752 relating to complementing cells and packaging systems for producing virus or viral particles
- 2760/18761 Methods of inactivation or attenuation
- 2760/18762 by genetic engineering
- 2760/18763 by chemical treatment
- 2760/18764 by serial passage
- 2760/18771 Demonstrated in vivo effect
- 2760/18788 for redistribution
- 2760/18811 Sendai virus
- 2760/18821 Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2760/18822 New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2760/18823 Virus like particles [VLP]
- 2760/18831 Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2760/18832 Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2760/18833 Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2760/18834 Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2760/18841 Use of virus, viral particle or viral elements as a vector
- 2760/18842 virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2760/18843 viral genome or elements thereof as genetic vector
- 2760/18845 Special targeting system for viral vectors
- 2760/18851 Methods of production or purification of viral material
- 2760/18852 relating to complementing cells and packaging systems for producing virus or viral particles
- 2760/18861 Methods of inactivation or attenuation
- 2760/18862 by genetic engineering
- 2760/18863 by chemical treatment
- 2760/18864 by serial passage
- 2760/18871 Demonstrated in vivo effect
- 2760/18888 for redistribution
- 2760/20011 Rhabdoviridae
- 2760/20021 Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2760/20022 New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2760/20023 Virus like particles [VLP]
- 2760/20031 Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2760/20032 Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2760/20033 Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory

- 2760/20034 . . . Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2760/20041 . . . Use of virus, viral particle or viral elements as a vector
- 2760/20042 virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2760/20043 viral genome or elements thereof as genetic vector
- 2760/20044 Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2760/20045 Special targeting system for viral vectors
- 2760/20051 . . . Methods of production or purification of viral material
- 2760/20052 relating to complementing cells and packaging systems for producing virus or viral particles
- 2760/20061 . . . Methods of inactivation or attenuation
- 2760/20062 by genetic engineering
- 2760/20063 by chemical treatment
- 2760/20064 by serial passage
- 2760/20071 . . . Demonstrated in vivo effect
- 2760/20088 . . . for redistribution
- 2760/20111 . . . Lyssavirus, e.g. rabies virus
- 2760/20121 Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2760/20122 New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2760/20123 Virus like particles [VLP]
- 2760/20131 Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2760/20132 Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2760/20133 Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2760/20134 Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2760/20141 Use of virus, viral particle or viral elements as a vector
- 2760/20142 virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2760/20143 viral genome or elements thereof as genetic vector
- 2760/20144 Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2760/20145 Special targeting system for viral vectors
- 2760/20151 Methods of production or purification of viral material
- 2760/20152 relating to complementing cells and packaging systems for producing virus or viral particles
- 2760/20161 Methods of inactivation or attenuation
- 2760/20162 by genetic engineering
- 2760/20163 by chemical treatment
- 2760/20164 by serial passage
- 2760/20171 Demonstrated in vivo effect
- 2760/20188 for redistribution
- 2760/20211 . . . Vesiculovirus, e.g. vesicular stomatitis Indiana virus
- 2760/20221 Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2760/20222 New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2760/20223 Virus like particles [VLP]
- 2760/20231 Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2760/20232 Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2760/20233 Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2760/20234 Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2760/20241 Use of virus, viral particle or viral elements as a vector
- 2760/20242 virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2760/20243 viral genome or elements thereof as genetic vector
- 2760/20244 Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2760/20245 Special targeting system for viral vectors
- 2760/20251 Methods of production or purification of viral material
- 2760/20252 relating to complementing cells and packaging systems for producing virus or viral particles
- 2760/20261 Methods of inactivation or attenuation
- 2760/20262 by genetic engineering
- 2760/20263 by chemical treatment
- 2760/20264 by serial passage
- 2760/20271 Demonstrated in vivo effect
- 2760/20288 for redistribution
- 2770/00** **ssRNA viruses positive-sense**
- 2770/00011 . Details
- 2770/00021 . . Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2770/00022 . . New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2770/00023 . . Virus like particles [VLP]
- 2770/00031 . . Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2770/00032 . . Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2770/00033 . . Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2770/00034 . . Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2770/00041 . . Use of virus, viral particle or viral elements as a vector
- 2770/00042 . . . virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2770/00043 . . . viral genome or elements thereof as genetic vector

- 2770/00044 . . . Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2770/00045 . . . Special targeting system for viral vectors
- 2770/00051 . . . Methods of production or purification of viral material
- 2770/00052 . . . relating to complementing cells and packaging systems for producing virus or viral particles
- 2770/00061 . . . Methods of inactivation or attenuation
- 2770/00062 . . . by genetic engineering
- 2770/00063 . . . by chemical treatment
- 2770/00064 . . . by serial passage
- 2770/00071 . . . Demonstrated in vivo effect
- 2770/00088 . . . for redistribution
- 2770/10011 . . . Arteriviridae
- 2770/10021 . . . Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2770/10022 . . . New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2770/10023 . . . Virus like particles [VLP]
- 2770/10031 . . . Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2770/10032 . . . Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2770/10033 . . . Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2770/10034 . . . Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2770/10041 . . . Use of virus, viral particle or viral elements as a vector
- 2770/10042 virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2770/10043 viral genome or elements thereof as genetic vector
- 2770/10044 Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2770/10045 Special targeting system for viral vectors
- 2770/10051 Methods of production or purification of viral material
- 2770/10052 relating to complementing cells and packaging systems for producing virus or viral particles
- 2770/10061 Methods of inactivation or attenuation
- 2770/10062 by genetic engineering
- 2770/10063 by chemical treatment
- 2770/10064 by serial passage
- 2770/10071 Demonstrated in vivo effect
- 2770/10088 for redistribution
- 2770/12011 . . . Astroviridae
- 2770/12021 . . . Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2770/12022 . . . New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2770/12023 . . . Virus like particles [VLP]
- 2770/12031 . . . Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2770/12032 . . . Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2770/12033 . . . Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2770/12034 . . . Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2770/12041 . . . Use of virus, viral particle or viral elements as a vector
- 2770/12042 virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2770/12043 viral genome or elements thereof as genetic vector
- 2770/12044 Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2770/12045 Special targeting system for viral vectors
- 2770/12051 Methods of production or purification of viral material
- 2770/12052 relating to complementing cells and packaging systems for producing virus or viral particles
- 2770/12061 Methods of inactivation or attenuation
- 2770/12062 by genetic engineering
- 2770/12063 by chemical treatment
- 2770/12064 by serial passage
- 2770/12071 Demonstrated in vivo effect
- 2770/12088 for redistribution
- 2770/14011 . . . Bromoviridae
- 2770/14021 . . . Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2770/14022 . . . New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2770/14023 . . . Virus like particles [VLP]
- 2770/14031 . . . Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2770/14032 . . . Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2770/14033 . . . Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2770/14034 . . . Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2770/14041 . . . Use of virus, viral particle or viral elements as a vector
- 2770/14042 virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2770/14043 viral genome or elements thereof as genetic vector
- 2770/14044 Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2770/14045 Special targeting system for viral vectors
- 2770/14051 Methods of production or purification of viral material
- 2770/14052 relating to complementing cells and packaging systems for producing virus or viral particles
- 2770/14061 Methods of inactivation or attenuation
- 2770/14062 by genetic engineering
- 2770/14063 by chemical treatment
- 2770/14064 by serial passage
- 2770/14071 Demonstrated in vivo effect

- 2770/14088 . . . for redistribution
- 2770/16011 . . Caliciviridae
- 2770/16021 . . . Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2770/16022 . . . New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2770/16023 . . . Virus like particles [VLP]
- 2770/16031 . . . Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2770/16032 . . . Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2770/16033 . . . Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2770/16034 . . . Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2770/16041 . . . Use of virus, viral particle or viral elements as a vector
- 2770/16042 virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2770/16043 viral genome or elements thereof as genetic vector
- 2770/16044 Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2770/16045 Special targeting system for viral vectors
- 2770/16051 . . . Methods of production or purification of viral material
- 2770/16052 relating to complementing cells and packaging systems for producing virus or viral particles
- 2770/16061 . . . Methods of inactivation or attenuation
- 2770/16062 by genetic engineering
- 2770/16063 by chemical treatment
- 2770/16064 by serial passage
- 2770/16071 . . . Demonstrated in vivo effect
- 2770/16088 . . . for redistribution
- 2770/18011 . . Comoviridae
- 2770/18021 . . . Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2770/18022 . . . New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2770/18023 . . . Virus like particles [VLP]
- 2770/18031 . . . Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2770/18032 . . . Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2770/18033 . . . Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2770/18034 . . . Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2770/18041 . . . Use of virus, viral particle or viral elements as a vector
- 2770/18042 virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2770/18043 viral genome or elements thereof as genetic vector
- 2770/18044 Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2770/18045 Special targeting system for viral vectors
- 2770/18051 . . . Methods of production or purification of viral material
- 2770/18052 relating to complementing cells and packaging systems for producing virus or viral particles
- 2770/18061 . . . Methods of inactivation or attenuation
- 2770/18062 by genetic engineering
- 2770/18063 by chemical treatment
- 2770/18064 by serial passage
- 2770/18071 . . . Demonstrated in vivo effect
- 2770/18088 . . . for redistribution
- 2770/20011 . . Coronaviridae
- 2770/20021 . . . Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2770/20022 . . . New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2770/20023 . . . Virus like particles [VLP]
- 2770/20031 . . . Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2770/20032 . . . Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2770/20033 . . . Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2770/20034 . . . Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2770/20041 . . . Use of virus, viral particle or viral elements as a vector
- 2770/20042 virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2770/20043 viral genome or elements thereof as genetic vector
- 2770/20044 Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2770/20045 Special targeting system for viral vectors
- 2770/20051 . . . Methods of production or purification of viral material
- 2770/20052 relating to complementing cells and packaging systems for producing virus or viral particles
- 2770/20061 . . . Methods of inactivation or attenuation
- 2770/20062 by genetic engineering
- 2770/20063 by chemical treatment
- 2770/20064 by serial passage
- 2770/20071 . . . Demonstrated in vivo effect
- 2770/20088 . . . for redistribution
- 2770/22011 . . Dicistroviridae
- 2770/22021 . . . Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2770/22022 . . . New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2770/22023 . . . Virus like particles [VLP]
- 2770/22031 . . . Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2770/22032 . . . Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent

- 2770/22033 . . . Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2770/22034 . . . Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2770/22041 . . . Use of virus, viral particle or viral elements as a vector
- 2770/22042 virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2770/22043 viral genome or elements thereof as genetic vector
- 2770/22044 Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2770/22045 Special targeting system for viral vectors
- 2770/22051 . . . Methods of production or purification of viral material
- 2770/22052 relating to complementing cells and packaging systems for producing virus or viral particles
- 2770/22061 . . . Methods of inactivation or attenuation
- 2770/22062 by genetic engineering
- 2770/22063 by chemical treatment
- 2770/22064 by serial passage
- 2770/22071 . . . Demonstrated in vivo effect
- 2770/22088 . . . for redistribution
- 2770/24011 . . Flaviviridae
- 2770/24021 . . . Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2770/24022 . . . New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2770/24023 . . . Virus like particles [VLP]
- 2770/24031 . . . Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2770/24032 . . . Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2770/24033 . . . Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2770/24034 . . . Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2770/24041 . . . Use of virus, viral particle or viral elements as a vector
- 2770/24042 virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2770/24043 viral genome or elements thereof as genetic vector
- 2770/24044 Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2770/24045 Special targeting system for viral vectors
- 2770/24051 . . . Methods of production or purification of viral material
- 2770/24052 relating to complementing cells and packaging systems for producing virus or viral particles
- 2770/24061 . . . Methods of inactivation or attenuation
- 2770/24062 by genetic engineering
- 2770/24063 by chemical treatment
- 2770/24064 by serial passage
- 2770/24071 . . . Demonstrated in vivo effect
- 2770/24088 . . . for redistribution
- 2770/24111 . . . Flavivirus, e.g. yellow fever virus, dengue, JEV
- 2770/24121 Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2770/24122 New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2770/24123 Virus like particles [VLP]
- 2770/24131 Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2770/24132 Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2770/24133 Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2770/24134 Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2770/24141 Use of virus, viral particle or viral elements as a vector
- 2770/24142 virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2770/24143 viral genome or elements thereof as genetic vector
- 2770/24144 Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2770/24145 Special targeting system for viral vectors
- 2770/24151 Methods of production or purification of viral material
- 2770/24152 relating to complementing cells and packaging systems for producing virus or viral particles
- 2770/24161 Methods of inactivation or attenuation
- 2770/24162 by genetic engineering
- 2770/24163 by chemical treatment
- 2770/24164 by serial passage
- 2770/24171 Demonstrated in vivo effect
- 2770/24188 for redistribution
- 2770/24211 . . . Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
- 2770/24221 Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2770/24222 New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2770/24223 Virus like particles [VLP]
- 2770/24231 Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2770/24232 Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2770/24233 Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2770/24234 Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2770/24241 Use of virus, viral particle or viral elements as a vector
- 2770/24242 virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2770/24243 viral genome or elements thereof as genetic vector

- 2770/24244 Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2770/24245 Special targeting system for viral vectors
- 2770/24251 Methods of production or purification of viral material
- 2770/24252 relating to complementing cells and packaging systems for producing virus or viral particles
- 2770/24261 Methods of inactivation or attenuation
- 2770/24262 by genetic engineering
- 2770/24263 by chemical treatment
- 2770/24264 by serial passage
- 2770/24271 Demonstrated *in vivo* effect
- 2770/24288 for redistribution
- 2770/24311 Pestivirus, e.g. bovine viral diarrhea virus
- 2770/24321 Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2770/24322 New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2770/24323 Virus like particles [VLP]
- 2770/24331 Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2770/24332 Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2770/24333 Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2770/24334 Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2770/24341 Use of virus, viral particle or viral elements as a vector
- 2770/24342 virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2770/24343 viral genome or elements thereof as genetic vector
- 2770/24344 Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2770/24345 Special targeting system for viral vectors
- 2770/24351 Methods of production or purification of viral material
- 2770/24352 relating to complementing cells and packaging systems for producing virus or viral particles
- 2770/24361 Methods of inactivation or attenuation
- 2770/24362 by genetic engineering
- 2770/24363 by chemical treatment
- 2770/24364 by serial passage
- 2770/24371 Demonstrated *in vivo* effect
- 2770/24388 for redistribution
- 2770/26011 . . Flexiviridae
- 2770/26021 Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2770/26022 New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2770/26023 Virus like particles [VLP]
- 2770/26031 Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2770/26032 Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2770/26033 Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2770/26034 Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2770/26041 Use of virus, viral particle or viral elements as a vector
- 2770/26042 virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2770/26043 viral genome or elements thereof as genetic vector
- 2770/26044 Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2770/26045 Special targeting system for viral vectors
- 2770/26051 Methods of production or purification of viral material
- 2770/26052 relating to complementing cells and packaging systems for producing virus or viral particles
- 2770/26061 Methods of inactivation or attenuation
- 2770/26062 by genetic engineering
- 2770/26063 by chemical treatment
- 2770/26064 by serial passage
- 2770/26071 Demonstrated *in vivo* effect
- 2770/26088 for redistribution
- 2770/28011 . . Hepeviridae
- 2770/28021 Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2770/28022 New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2770/28023 Virus like particles [VLP]
- 2770/28031 Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2770/28032 Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2770/28033 Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2770/28034 Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2770/28041 Use of virus, viral particle or viral elements as a vector
- 2770/28042 virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2770/28043 viral genome or elements thereof as genetic vector
- 2770/28044 Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2770/28045 Special targeting system for viral vectors
- 2770/28051 Methods of production or purification of viral material
- 2770/28052 relating to complementing cells and packaging systems for producing virus or viral particles
- 2770/28061 Methods of inactivation or attenuation
- 2770/28062 by genetic engineering
- 2770/28063 by chemical treatment
- 2770/28064 by serial passage
- 2770/28071 Demonstrated *in vivo* effect

- 2770/28088 . . . for redistribution
- 2770/28111 . . . Hepevirus, e.g. hepatitis E virus
- 2770/28121 Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2770/28122 New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2770/28123 Virus like particles [VLP]
- 2770/28131 Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2770/28132 Use of virus as therapeutic agent, other than vaccine, e.g. as cytolitic agent
- 2770/28133 Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2770/28134 Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2770/28141 Use of virus, viral particle or viral elements as a vector
- 2770/28142 virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2770/28143 viral genome or elements thereof as genetic vector
- 2770/28144 Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2770/28145 Special targeting system for viral vectors
- 2770/28151 Methods of production or purification of viral material
- 2770/28152 relating to complementing cells and packaging systems for producing virus or viral particles
- 2770/28161 Methods of inactivation or attenuation
- 2770/28162 by genetic engineering
- 2770/28163 by chemical treatment
- 2770/28164 by serial passage
- 2770/28171 Demonstrated *in vivo* effect
- 2770/28188 for redistribution
- 2770/30011 . . . Nodaviridae
- 2770/30021 Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2770/30022 New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2770/30023 Virus like particles [VLP]
- 2770/30031 Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2770/30032 Use of virus as therapeutic agent, other than vaccine, e.g. as cytolitic agent
- 2770/30033 Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2770/30034 Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2770/30041 Use of virus, viral particle or viral elements as a vector
- 2770/30042 virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2770/30043 viral genome or elements thereof as genetic vector
- 2770/30044 Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2770/30045 Special targeting system for viral vectors
- 2770/30051 Methods of production or purification of viral material
- 2770/30052 relating to complementing cells and packaging systems for producing virus or viral particles
- 2770/30061 Methods of inactivation or attenuation
- 2770/30062 by genetic engineering
- 2770/30063 by chemical treatment
- 2770/30064 by serial passage
- 2770/30071 Demonstrated *in vivo* effect
- 2770/30088 for redistribution
- 2770/32011 . . . Picornaviridae
- 2770/32021 Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2770/32022 New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2770/32023 Virus like particles [VLP]
- 2770/32031 Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2770/32032 Use of virus as therapeutic agent, other than vaccine, e.g. as cytolitic agent
- 2770/32033 Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2770/32034 Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2770/32041 Use of virus, viral particle or viral elements as a vector
- 2770/32042 virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2770/32043 viral genome or elements thereof as genetic vector
- 2770/32044 Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2770/32045 Special targeting system for viral vectors
- 2770/32051 Methods of production or purification of viral material
- 2770/32052 relating to complementing cells and packaging systems for producing virus or viral particles
- 2770/32061 Methods of inactivation or attenuation
- 2770/32062 by genetic engineering
- 2770/32063 by chemical treatment
- 2770/32064 by serial passage
- 2770/32071 Demonstrated *in vivo* effect
- 2770/32088 for redistribution
- 2770/32111 Aphthovirus, e.g. footandmouth disease virus
- 2770/32121 Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2770/32122 New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2770/32123 Virus like particles [VLP]
- 2770/32131 Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2770/32132 Use of virus as therapeutic agent, other than vaccine, e.g. as cytolitic agent

- 2770/32133 Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2770/32134 Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2770/32141 Use of virus, viral particle or viral elements as a vector
- 2770/32142 virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2770/32143 viral genome or elements thereof as genetic vector
- 2770/32144 Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2770/32145 Special targeting system for viral vectors
- 2770/32151 Methods of production or purification of viral material
- 2770/32152 relating to complementing cells and packaging systems for producing virus or viral particles
- 2770/32161 Methods of inactivation or attenuation
- 2770/32162 by genetic engineering
- 2770/32163 by chemical treatment
- 2770/32164 by serial passage
- 2770/32171 Demonstrated *in vivo* effect
- 2770/32188 for redistribution
- 2770/32211 Cardiovirus, e.g. encephalomyocarditis virus
- 2770/32221 Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2770/32222 New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2770/32223 Virus like particles [VLP]
- 2770/32231 Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2770/32232 Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2770/32233 Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2770/32234 Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2770/32241 Use of virus, viral particle or viral elements as a vector
- 2770/32242 virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2770/32243 viral genome or elements thereof as genetic vector
- 2770/32244 Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2770/32245 Special targeting system for viral vectors
- 2770/32251 Methods of production or purification of viral material
- 2770/32252 relating to complementing cells and packaging systems for producing virus or viral particles
- 2770/32261 Methods of inactivation or attenuation
- 2770/32262 by genetic engineering
- 2770/32263 by chemical treatment
- 2770/32264 by serial passage
- 2770/32271 Demonstrated *in vivo* effect
- 2770/32288 for redistribution
- 2770/32311 Enterovirus
- 2770/32321 Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2770/32322 New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2770/32323 Virus like particles [VLP]
- 2770/32331 Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2770/32332 Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2770/32333 Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2770/32334 Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2770/32341 Use of virus, viral particle or viral elements as a vector
- 2770/32342 virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2770/32343 viral genome or elements thereof as genetic vector
- 2770/32344 Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2770/32345 Special targeting system for viral vectors
- 2770/32351 Methods of production or purification of viral material
- 2770/32352 relating to complementing cells and packaging systems for producing virus or viral particles
- 2770/32361 Methods of inactivation or attenuation
- 2770/32362 by genetic engineering
- 2770/32363 by chemical treatment
- 2770/32364 by serial passage
- 2770/32371 Demonstrated *in vivo* effect
- 2770/32388 for redistribution
- 2770/32411 Hepatovirus, i.e. hepatitis A virus
- 2770/32421 Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2770/32422 New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2770/32423 Virus like particles [VLP]
- 2770/32431 Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2770/32432 Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2770/32433 Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2770/32434 Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2770/32441 Use of virus, viral particle or viral elements as a vector
- 2770/32442 virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2770/32443 viral genome or elements thereof as genetic vector

- 2770/32444 Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2770/32445 Special targeting system for viral vectors
- 2770/32451 Methods of production or purification of viral material
- 2770/32452 relating to complementing cells and packaging systems for producing virus or viral particles
- 2770/32461 Methods of inactivation or attenuation
- 2770/32462 by genetic engineering
- 2770/32463 by chemical treatment
- 2770/32464 by serial passage
- 2770/32471 Demonstrated *in vivo* effect
- 2770/32488 for redistribution
- 2770/32511 . . . Parechovirus, e.g. human parechovirus
- 2770/32521 Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2770/32522 New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2770/32523 Virus like particles [VLP]
- 2770/32531 Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2770/32532 Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2770/32533 Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2770/32534 Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2770/32541 Use of virus, viral particle or viral elements as a vector
- 2770/32542 virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2770/32543 viral genome or elements thereof as genetic vector
- 2770/32544 Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2770/32545 Special targeting system for viral vectors
- 2770/32551 Methods of production or purification of viral material
- 2770/32552 relating to complementing cells and packaging systems for producing virus or viral particles
- 2770/32561 Methods of inactivation or attenuation
- 2770/32562 by genetic engineering
- 2770/32563 by chemical treatment
- 2770/32564 by serial passage
- 2770/32571 Demonstrated *in vivo* effect
- 2770/32588 for redistribution
- 2770/32611 . . . Poliovirus
- 2770/32621 Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2770/32622 New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2770/32623 Virus like particles [VLP]
- 2770/32631 Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2770/32632 Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2770/32633 Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2770/32634 Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2770/32641 Use of virus, viral particle or viral elements as a vector
- 2770/32642 virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2770/32643 viral genome or elements thereof as genetic vector
- 2770/32644 Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2770/32645 Special targeting system for viral vectors
- 2770/32651 Methods of production or purification of viral material
- 2770/32652 relating to complementing cells and packaging systems for producing virus or viral particles
- 2770/32661 Methods of inactivation or attenuation
- 2770/32662 by genetic engineering
- 2770/32663 by chemical treatment
- 2770/32664 by serial passage
- 2770/32671 Demonstrated *in vivo* effect
- 2770/32688 for redistribution
- 2770/32711 . . . Rhinovirus
- 2770/32721 Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2770/32722 New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2770/32723 Virus like particles [VLP]
- 2770/32731 Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2770/32732 Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2770/32733 Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2770/32734 Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2770/32741 Use of virus, viral particle or viral elements as a vector
- 2770/32742 virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2770/32743 viral genome or elements thereof as genetic vector
- 2770/32744 Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2770/32745 Special targeting system for viral vectors
- 2770/32751 Methods of production or purification of viral material
- 2770/32752 relating to complementing cells and packaging systems for producing virus or viral particles
- 2770/32761 Methods of inactivation or attenuation
- 2770/32762 by genetic engineering
- 2770/32763 by chemical treatment
- 2770/32764 by serial passage
- 2770/32771 Demonstrated *in vivo* effect

- 2770/32788 for redistribution
- 2770/34011 . . . Potyviridae
- 2770/34021 . . . Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2770/34022 . . . New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2770/34023 . . . Virus like particles [VLP]
- 2770/34031 . . . Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2770/34032 . . . Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2770/34033 . . . Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2770/34034 . . . Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2770/34041 . . . Use of virus, viral particle or viral elements as a vector
- 2770/34042 virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2770/34043 viral genome or elements thereof as genetic vector
- 2770/34044 Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2770/34045 Special targeting system for viral vectors
- 2770/34051 . . . Methods of production or purification of viral material
- 2770/34052 relating to complementing cells and packaging systems for producing virus or viral particles
- 2770/34061 . . . Methods of inactivation or attenuation
- 2770/34062 by genetic engineering
- 2770/34063 by chemical treatment
- 2770/34064 by serial passage
- 2770/34071 . . . Demonstrated in vivo effect
- 2770/34088 . . . for redistribution
- 2770/36011 . . . Togaviridae
- 2770/36021 . . . Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2770/36022 . . . New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2770/36023 . . . Virus like particles [VLP]
- 2770/36031 . . . Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2770/36032 . . . Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2770/36033 . . . Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2770/36034 . . . Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2770/36041 . . . Use of virus, viral particle or viral elements as a vector
- 2770/36042 virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2770/36043 viral genome or elements thereof as genetic vector
- 2770/36044 Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2770/36045 Special targeting system for viral vectors
- 2770/36051 . . . Methods of production or purification of viral material
- 2770/36052 relating to complementing cells and packaging systems for producing virus or viral particles
- 2770/36061 . . . Methods of inactivation or attenuation
- 2770/36062 by genetic engineering
- 2770/36063 by chemical treatment
- 2770/36064 by serial passage
- 2770/36071 . . . Demonstrated in vivo effect
- 2770/36088 . . . for redistribution
- 2770/36111 . . . Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
- 2770/36121 Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2770/36122 New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2770/36123 Virus like particles [VLP]
- 2770/36131 Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2770/36132 Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2770/36133 Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2770/36134 Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2770/36141 Use of virus, viral particle or viral elements as a vector
- 2770/36142 virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2770/36143 viral genome or elements thereof as genetic vector
- 2770/36144 Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2770/36145 Special targeting system for viral vectors
- 2770/36151 Methods of production or purification of viral material
- 2770/36152 relating to complementing cells and packaging systems for producing virus or viral particles
- 2770/36161 Methods of inactivation or attenuation
- 2770/36162 by genetic engineering
- 2770/36163 by chemical treatment
- 2770/36164 by serial passage
- 2770/36171 Demonstrated in vivo effect
- 2770/36188 for redistribution
- 2770/36211 . . . Rubivirus, e.g. rubella virus
- 2770/36221 Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2770/36222 New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2770/36223 Virus like particles [VLP]
- 2770/36231 Uses of virus other than therapeutic or vaccine, e.g. disinfectant

- 2770/36232 Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2770/36233 Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2770/36234 Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2770/36241 Use of virus, viral particle or viral elements as a vector
- 2770/36242 virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2770/36243 viral genome or elements thereof as genetic vector
- 2770/36244 Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2770/36245 Special targeting system for viral vectors
- 2770/36251 Methods of production or purification of viral material
- 2770/36252 relating to complementing cells and packaging systems for producing virus or viral particles
- 2770/36261 Methods of inactivation or attenuation
- 2770/36262 by genetic engineering
- 2770/36263 by chemical treatment
- 2770/36264 by serial passage
- 2770/36271 Demonstrated *in vivo* effect
- 2770/36288 for redistribution
- 2770/38011 Tombusviridae
- 2770/38021 Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2770/38022 New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2770/38023 Virus like particles [VLP]
- 2770/38031 Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2770/38032 Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2770/38033 Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2770/38034 Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2770/38041 Use of virus, viral particle or viral elements as a vector
- 2770/38042 virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2770/38043 viral genome or elements thereof as genetic vector
- 2770/38044 Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2770/38045 Special targeting system for viral vectors
- 2770/38051 Methods of production or purification of viral material
- 2770/38052 relating to complementing cells and packaging systems for producing virus or viral particles
- 2770/38061 Methods of inactivation or attenuation
- 2770/38062 by genetic engineering
- 2770/38063 by chemical treatment
- 2770/38064 by serial passage
- 2770/38071 Demonstrated *in vivo* effect
- 2770/38088 for redistribution
- 2770/40011 Tymoviridae
- 2770/40021 Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2770/40022 New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2770/40023 Virus like particles [VLP]
- 2770/40031 Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2770/40032 Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2770/40033 Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2770/40034 Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2770/40041 Use of virus, viral particle or viral elements as a vector
- 2770/40042 virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2770/40043 viral genome or elements thereof as genetic vector
- 2770/40044 Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2770/40045 Special targeting system for viral vectors
- 2770/40051 Methods of production or purification of viral material
- 2770/40052 relating to complementing cells and packaging systems for producing virus or viral particles
- 2770/40061 Methods of inactivation or attenuation
- 2770/40062 by genetic engineering
- 2770/40063 by chemical treatment
- 2770/40064 by serial passage
- 2770/40071 Demonstrated *in vivo* effect
- 2770/40088 for redistribution
- 2780/00** **Naked RNA viruses**
- 2780/00011 Details
- 2780/00021 Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2780/00022 New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2780/00023 Virus like particles [VLP]
- 2780/00031 Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2780/00032 Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2780/00033 Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2780/00034 Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2780/00041 Use of virus, viral particle or viral elements as a vector
- 2780/00042 virus or viral particle as vehicle, e.g. encapsulating small organic molecule

- 2780/00043 . . . viral genome or elements thereof as genetic vector
- 2780/00044 . . . Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2780/00045 . . . Special targeting system for viral vectors
- 2780/00051 . . Methods of production or purification of viral material
- 2780/00052 . . . relating to complementing cells and packaging systems for producing virus or viral particles
- 2780/00061 . . Methods of inactivation or attenuation
- 2780/00062 . . . by genetic engineering
- 2780/00063 . . . by chemical treatment
- 2780/00064 . . . by serial passage
- 2780/00071 . . Demonstrated in vivo effect
- 2780/00088 . . for redistribution
- 2780/10011 . . Narnaviridae
- 2780/10021 . . . Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2780/10022 . . . New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2780/10023 . . . Virus like particles [VLP]
- 2780/10031 . . . Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2780/10032 . . . Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2780/10033 . . . Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2780/10034 . . . Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2780/10041 . . . Use of virus, viral particle or viral elements as a vector
- 2780/10042 virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2780/10043 viral genome or elements thereof as genetic vector
- 2780/10044 Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2780/10045 Special targeting system for viral vectors
- 2780/10051 . . . Methods of production or purification of viral material
- 2780/10052 relating to complementing cells and packaging systems for producing virus or viral particles
- 2780/10061 . . . Methods of inactivation or attenuation
- 2780/10062 by genetic engineering
- 2780/10063 by chemical treatment
- 2780/10064 by serial passage
- 2780/10071 . . . Demonstrated in vivo effect
- 2780/10088 . . . for redistribution
- 2790/00** **Viroids or subviral agents**
- 2790/00011 . Details
- 2790/00021 . . Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2790/00022 . . New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2790/00023 . . Virus like particles [VLP]
- 2790/00031 . . Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2790/00032 . . Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2790/00033 . . Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2790/00034 . . Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2790/00041 . . Use of virus, viral particle or viral elements as a vector
- 2790/00042 virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2790/00043 viral genome or elements thereof as genetic vector
- 2790/00044 Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2790/00045 Special targeting system for viral vectors
- 2790/00051 . . . Methods of production or purification of viral material
- 2790/00052 relating to complementing cells and packaging systems for producing virus or viral particles
- 2790/00061 . . Methods of inactivation or attenuation
- 2790/00062 by genetic engineering
- 2790/00063 by chemical treatment
- 2790/00064 by serial passage
- 2790/00071 . . Demonstrated in vivo effect
- 2790/00088 . . for redistribution
- 2790/10011 . . Prions
- 2790/10021 . . . Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2790/10022 . . . New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2790/10023 . . . Virus like particles [VLP]
- 2790/10031 . . . Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2790/10032 . . . Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2790/10033 . . . Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2790/10034 . . . Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2790/10041 . . . Use of virus, viral particle or viral elements as a vector
- 2790/10042 virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2790/10043 viral genome or elements thereof as genetic vector
- 2790/10044 Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2790/10045 Special targeting system for viral vectors
- 2790/10051 . . . Methods of production or purification of viral material
- 2790/10052 relating to complementing cells and packaging systems for producing virus or viral particles
- 2790/10061 . . . Methods of inactivation or attenuation
- 2790/10062 by genetic engineering

- 2790/10063 by chemical treatment
- 2790/10064 by serial passage
- 2790/10071 Demonstrated in vivo effect
- 2790/10088 for redistribution
- 2790/12011 Satellite viruses
- 2790/12021 Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2790/12022 New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2790/12023 Virus like particles [VLP]
- 2790/12031 Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2790/12032 Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2790/12033 Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2790/12034 Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2790/12041 Use of virus, viral particle or viral elements as a vector
- 2790/12042 virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2790/12043 viral genome or elements thereof as genetic vector
- 2790/12044 Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2790/12045 Special targeting system for viral vectors
- 2790/12051 Methods of production or purification of viral material
- 2790/12052 relating to complementing cells and packaging systems for producing virus or viral particles
- 2790/12061 Methods of inactivation or attenuation
- 2790/12062 by genetic engineering
- 2790/12063 by chemical treatment
- 2790/12064 by serial passage
- 2790/12071 Demonstrated in vivo effect
- 2790/12088 for redistribution
- 2790/14011 Viroids
- 2790/14021 Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2790/14022 New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2790/14023 Virus like particles [VLP]
- 2790/14031 Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2790/14032 Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2790/14033 Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2790/14034 Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2790/14041 Use of virus, viral particle or viral elements as a vector
- 2790/14042 virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2790/14043 viral genome or elements thereof as genetic vector
- 2790/14044 Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2790/14045 Special targeting system for viral vectors
- 2790/14051 Methods of production or purification of viral material
- 2790/14052 relating to complementing cells and packaging systems for producing virus or viral particles
- 2790/14061 Methods of inactivation or attenuation
- 2790/14062 by genetic engineering
- 2790/14063 by chemical treatment
- 2790/14064 by serial passage
- 2790/14071 Demonstrated in vivo effect
- 2790/14088 for redistribution
- 2792/00** **Archaeobacteria viruses**
- 2792/00011 Details
- 2792/00021 Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2792/00022 New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2792/00023 Virus like particles [VLP]
- 2792/00031 Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2792/00032 Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2792/00033 Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2792/00034 Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2792/00041 Use of virus, viral particle or viral elements as a vector
- 2792/00042 virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2792/00043 viral genome or elements thereof as genetic vector
- 2792/00044 Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2792/00045 Special targeting system for viral vectors
- 2792/00051 Methods of production or purification of viral material
- 2792/00052 relating to complementing cells and packaging systems for producing virus or viral particles
- 2792/00061 Methods of inactivation or attenuation
- 2792/00062 by genetic engineering
- 2792/00063 by chemical treatment
- 2792/00064 by serial passage
- 2792/00071 Demonstrated in vivo effect
- 2792/00088 for redistribution
- 2792/10011 Fuselloviridae
- 2792/10021 Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2792/10022 New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2792/10023 Virus like particles [VLP]

- 2792/10031 . . . Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2792/10032 . . . Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2792/10033 . . . Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2792/10034 . . . Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2792/10041 . . . Use of virus, viral particle or viral elements as a vector
- 2792/10042 virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2792/10043 viral genome or elements thereof as genetic vector
- 2792/10044 Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2792/10045 Special targeting system for viral vectors
- 2792/10051 . . . Methods of production or purification of viral material
- 2792/10052 relating to complementing cells and packaging systems for producing virus or viral particles
- 2792/10061 . . . Methods of inactivation or attenuation
- 2792/10062 by genetic engineering
- 2792/10063 by chemical treatment
- 2792/10064 by serial passage
- 2792/10071 . . . Demonstrated in vivo effect
- 2792/10088 . . . for redistribution
- 2792/12011 . . Guttaviridae
- 2792/12021 . . . Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2792/12022 . . . New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2792/12023 . . . Virus like particles [VLP]
- 2792/12031 . . . Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2792/12032 . . . Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2792/12033 . . . Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2792/12034 . . . Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2792/12041 . . . Use of virus, viral particle or viral elements as a vector
- 2792/12042 virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2792/12043 viral genome or elements thereof as genetic vector
- 2792/12044 Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2792/12045 Special targeting system for viral vectors
- 2792/12051 . . . Methods of production or purification of viral material
- 2792/12052 relating to complementing cells and packaging systems for producing virus or viral particles
- 2792/12061 . . . Methods of inactivation or attenuation
- 2792/12062 by genetic engineering
- 2792/12063 by chemical treatment
- 2792/12064 by serial passage
- 2792/12071 . . . Demonstrated in vivo effect
- 2792/12088 . . . for redistribution
- 2795/00** **Bacteriophages**
- 2795/00011 . Details
- 2795/00021 . . Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2795/00022 . . New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2795/00023 . . Virus like particles [VLP]
- 2795/00031 . . Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2795/00032 . . Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2795/00033 . . Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2795/00034 . . Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2795/00041 . . Use of virus, viral particle or viral elements as a vector
- 2795/00042 . . . virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2795/00043 . . . viral genome or elements thereof as genetic vector
- 2795/00044 . . . Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2795/00045 . . . Special targeting system for viral vectors
- 2795/00051 . . Methods of production or purification of viral material
- 2795/00052 . . . relating to complementing cells and packaging systems for producing virus or viral particles
- 2795/00061 . . Methods of inactivation or attenuation
- 2795/00062 . . . by genetic engineering
- 2795/00063 . . . by chemical treatment
- 2795/00064 . . . by serial passage
- 2795/00071 . . Demonstrated in vivo effect
- 2795/00088 . . for redistribution
- 2795/10011 . . dsDNA Bacteriophages
- 2795/10021 . . . Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2795/10022 . . . New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2795/10023 . . . Virus like particles [VLP]
- 2795/10031 . . . Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2795/10032 . . . Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2795/10033 . . . Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2795/10034 . . . Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2795/10041 . . . Use of virus, viral particle or viral elements as a vector

- 2795/10042 virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2795/10043 viral genome or elements thereof as genetic vector
- 2795/10044 Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2795/10045 Special targeting system for viral vectors
- 2795/10051 Methods of production or purification of viral material
- 2795/10052 relating to complementing cells and packaging systems for producing virus or viral particles
- 2795/10061 Methods of inactivation or attenuation
- 2795/10062 by genetic engineering
- 2795/10063 by chemical treatment
- 2795/10064 by serial passage
- 2795/10071 Demonstrated in vivo effect
- 2795/10088 for redistribution
- 2795/10111 Myoviridae
- 2795/10121 Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2795/10122 New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2795/10123 Virus like particles [VLP]
- 2795/10131 Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2795/10132 Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2795/10133 Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2795/10134 Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2795/10141 Use of virus, viral particle or viral elements as a vector
- 2795/10142 virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2795/10143 viral genome or elements thereof as genetic vector
- 2795/10144 Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2795/10145 Special targeting system for viral vectors
- 2795/10151 Methods of production or purification of viral material
- 2795/10152 relating to complementing cells and packaging systems for producing virus or viral particles
- 2795/10161 Methods of inactivation or attenuation
- 2795/10162 by genetic engineering
- 2795/10163 by chemical treatment
- 2795/10164 by serial passage
- 2795/10171 Demonstrated in vivo effect
- 2795/10188 for redistribution
- 2795/10211 Podoviridae
- 2795/10221 Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2795/10222 New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2795/10223 Virus like particles [VLP]
- 2795/10231 Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2795/10232 Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2795/10233 Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2795/10234 Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2795/10241 Use of virus, viral particle or viral elements as a vector
- 2795/10242 virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2795/10243 viral genome or elements thereof as genetic vector
- 2795/10244 Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2795/10245 Special targeting system for viral vectors
- 2795/10251 Methods of production or purification of viral material
- 2795/10252 relating to complementing cells and packaging systems for producing virus or viral particles
- 2795/10261 Methods of inactivation or attenuation
- 2795/10262 by genetic engineering
- 2795/10263 by chemical treatment
- 2795/10264 by serial passage
- 2795/10271 Demonstrated in vivo effect
- 2795/10288 for redistribution
- 2795/10311 Siphoviridae
- 2795/10321 Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2795/10322 New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2795/10323 Virus like particles [VLP]
- 2795/10331 Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2795/10332 Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2795/10333 Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2795/10334 Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2795/10341 Use of virus, viral particle or viral elements as a vector
- 2795/10342 virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2795/10343 viral genome or elements thereof as genetic vector
- 2795/10344 Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2795/10345 Special targeting system for viral vectors
- 2795/10351 Methods of production or purification of viral material
- 2795/10352 relating to complementing cells and packaging systems for producing virus or viral particles
- 2795/10361 Methods of inactivation or attenuation

- 2795/10362 by genetic engineering
- 2795/10363 by chemical treatment
- 2795/10364 by serial passage
- 2795/10371 Demonstrated in vivo effect
- 2795/10388 for redistribution
- 2795/12011 . . . dsRNA Bacteriophages
- 2795/12021 . . . Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2795/12022 . . . New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2795/12023 . . . Virus like particles [VLP]
- 2795/12031 . . . Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2795/12032 . . . Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2795/12033 . . . Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2795/12034 . . . Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2795/12041 . . . Use of virus, viral particle or viral elements as a vector
- 2795/12042 virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2795/12043 viral genome or elements thereof as genetic vector
- 2795/12044 Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2795/12045 Special targeting system for viral vectors
- 2795/12051 . . . Methods of production or purification of viral material
- 2795/12052 relating to complementing cells and packaging systems for producing virus or viral particles
- 2795/12061 . . . Methods of inactivation or attenuation
- 2795/12062 by genetic engineering
- 2795/12063 by chemical treatment
- 2795/12064 by serial passage
- 2795/12071 . . . Demonstrated in vivo effect
- 2795/12088 . . . for redistribution
- 2795/14011 . . . ssDNA Bacteriophages
- 2795/14021 . . . Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2795/14022 . . . New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2795/14023 . . . Virus like particles [VLP]
- 2795/14031 . . . Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2795/14032 . . . Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2795/14033 . . . Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2795/14034 . . . Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2795/14041 . . . Use of virus, viral particle or viral elements as a vector
- 2795/14042 virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2795/14043 viral genome or elements thereof as genetic vector
- 2795/14044 Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2795/14045 Special targeting system for viral vectors
- 2795/14051 . . . Methods of production or purification of viral material
- 2795/14052 relating to complementing cells and packaging systems for producing virus or viral particles
- 2795/14061 . . . Methods of inactivation or attenuation
- 2795/14062 by genetic engineering
- 2795/14063 by chemical treatment
- 2795/14064 by serial passage
- 2795/14071 . . . Demonstrated in vivo effect
- 2795/14088 . . . for redistribution
- 2795/14111 . . . Inoviridae
- 2795/14121 Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2795/14122 New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2795/14123 Virus like particles [VLP]
- 2795/14131 Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2795/14132 Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- 2795/14133 Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2795/14134 Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2795/14141 Use of virus, viral particle or viral elements as a vector
- 2795/14142 virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2795/14143 viral genome or elements thereof as genetic vector
- 2795/14144 Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2795/14145 Special targeting system for viral vectors
- 2795/14151 Methods of production or purification of viral material
- 2795/14152 relating to complementing cells and packaging systems for producing virus or viral particles
- 2795/14161 Methods of inactivation or attenuation
- 2795/14162 by genetic engineering
- 2795/14163 by chemical treatment
- 2795/14164 by serial passage
- 2795/14171 Demonstrated in vivo effect
- 2795/14188 for redistribution
- 2795/14211 . . . Microviridae
- 2795/14221 Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2795/14222 New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2795/14223 Virus like particles [VLP]
- 2795/14231 Uses of virus other than therapeutic or vaccine, e.g. disinfectant

- 2795/14232 Use of virus as therapeutic agent, other than vaccine, e.g. as cytolitic agent
- 2795/14233 Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2795/14234 Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2795/14241 Use of virus, viral particle or viral elements as a vector
- 2795/14242 virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2795/14243 viral genome or elements thereof as genetic vector
- 2795/14244 Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2795/14245 Special targeting system for viral vectors
- 2795/14251 Methods of production or purification of viral material
- 2795/14252 relating to complementing cells and packaging systems for producing virus or viral particles
- 2795/14261 Methods of inactivation or attenuation
- 2795/14262 by genetic engineering
- 2795/14263 by chemical treatment
- 2795/14264 by serial passage
- 2795/14271 Demonstrated *in vivo* effect
- 2795/14288 for redistribution
- 2795/16011 . . ssRNA Bacteriophages negative-sense
- 2795/16021 . . . Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2795/16022 . . . New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2795/16023 . . . Virus like particles [VLP]
- 2795/16031 . . . Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2795/16032 . . . Use of virus as therapeutic agent, other than vaccine, e.g. as cytolitic agent
- 2795/16033 . . . Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2795/16034 . . . Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2795/16041 . . . Use of virus, viral particle or viral elements as a vector
- 2795/16042 virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2795/16043 viral genome or elements thereof as genetic vector
- 2795/16044 Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2795/16045 Special targeting system for viral vectors
- 2795/16051 Methods of production or purification of viral material
- 2795/16052 relating to complementing cells and packaging systems for producing virus or viral particles
- 2795/16061 Methods of inactivation or attenuation
- 2795/16062 by genetic engineering
- 2795/16063 by chemical treatment
- 2795/16064 by serial passage
- 2795/16071 Demonstrated *in vivo* effect
- 2795/16088 for redistribution
- 2795/18011 . . . ssRNA Bacteriophages positive-sense
- 2795/18021 . . . Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2795/18022 . . . New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2795/18023 Virus like particles [VLP]
- 2795/18031 Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2795/18032 Use of virus as therapeutic agent, other than vaccine, e.g. as cytolitic agent
- 2795/18033 Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2795/18034 Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2795/18041 Use of virus, viral particle or viral elements as a vector
- 2795/18042 virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2795/18043 viral genome or elements thereof as genetic vector
- 2795/18044 Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2795/18045 Special targeting system for viral vectors
- 2795/18051 Methods of production or purification of viral material
- 2795/18052 relating to complementing cells and packaging systems for producing virus or viral particles
- 2795/18061 Methods of inactivation or attenuation
- 2795/18062 by genetic engineering
- 2795/18063 by chemical treatment
- 2795/18064 by serial passage
- 2795/18071 Demonstrated *in vivo* effect
- 2795/18088 for redistribution
- 2795/18111 Leviviridae
- 2795/18121 Viruses as such, e.g. new isolates, mutants or their genomic sequences
- 2795/18122 New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- 2795/18123 Virus like particles [VLP]
- 2795/18131 Uses of virus other than therapeutic or vaccine, e.g. disinfectant
- 2795/18132 Use of virus as therapeutic agent, other than vaccine, e.g. as cytolitic agent
- 2795/18133 Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- 2795/18134 Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- 2795/18141 Use of virus, viral particle or viral elements as a vector
- 2795/18142 virus or viral particle as vehicle, e.g. encapsulating small organic molecule
- 2795/18143 viral genome or elements thereof as genetic vector

- 2795/18144 Chimeric viral vector comprising heterologous viral elements for production of another viral vector
- 2795/18145 Special targeting system for viral vectors
- 2795/18151 Methods of production or purification of viral material
- 2795/18152 relating to complementing cells and packaging systems for producing virus or viral particles
- 2795/18161 Methods of inactivation or attenuation
- 2795/18162 by genetic engineering
- 2795/18163 by chemical treatment
- 2795/18164 by serial passage
- 2795/18171 Demonstrated *in vivo* effect
- 2795/18188 for redistribution
- 2796/00** **Viruses not covered by groups**
[C12N 2710/00](#) - [C12N 2795/00](#)
- 2799/00** **Uses of viruses**
- WARNING**
- From March 15, 2012 codes in the range [C12N 2799/00](#) - [C12N 2799/06](#) are no longer used for the classification of new documents. The documents in this range are being reclassified to the corresponding codes in [C12N 2710/00](#)-[C12N 2795/00](#)
- 2799/02 . . as vector
- 2799/021 . . for the expression of a heterologous nucleic acid
- 2799/022 . . . where the vector is derived from an adenovirus
- 2799/023 . . . where the vector is derived from a poxvirus
- 2799/025 . . . where the vector is derived from a parvovirus
- 2799/026 . . . where the vector is derived from a baculovirus
- 2799/027 . . . where the vector is derived from a retrovirus
- 2799/028 . . . where the vector is derived from a herpesvirus
- 2799/04 . . *in vivo*
- 2799/06 . . *in vitro*
- 2800/00** **Nucleic acids vectors**
- 2800/10 . . Plasmid DNA
- 2800/101 . . for bacteria
- 2800/102 . . for yeast
- 2800/103 . . for invertebrates
- 2800/105 . . . for insects
- 2800/106 . . for vertebrates
- 2800/107 . . . for mammalian
- 2800/108 . . episomal vectors
- 2800/20 . . Pseudochromosomes, minichromosomes
- 2800/202 . . of bacteriophage origin
- 2800/204 . . of bacterial origin, e.g. BAC
- 2800/206 . . of yeast origin, e.g. YAC, 2u
- 2800/208 . . of mammalian origin, e.g. minichromosome
- 2800/22 . . Vectors comprising a coding region that has been codon optimised for expression in a respective host
- 2800/24 . . Vectors characterised by the absence of particular element, e.g. selectable marker, viral origin of replication
- 2800/30 . . Vector systems comprising sequences for excision in presence of a recombinase, e.g. loxP or FRT
- 2800/40 . . Systems of functionally co-operating vectors
- 2800/50 . . Vectors for producing vectors
- 2800/60 . . Vectors containing traps for, e.g. exons, promoters
- 2800/70 . . Vectors containing special elements for cloning, e.g. topoisomerase, adaptor sites
- 2800/80 . . Vectors containing sites for inducing double-stranded breaks, e.g. meganuclease restriction sites
- 2800/90 . . Vectors containing a transposable element
- 2800/95 . . Protection of vectors from inactivation by agents such as antibodies or enzymes, e.g. using polymers
- 2810/00** **Vectors comprising a targeting moiety**
- 2810/10 . . Vectors comprising a non-peptidic targeting moiety
- 2810/40 . . Vectors comprising a peptide as targeting moiety, e.g. a synthetic peptide, from undefined source
- 2810/405 . . Vectors comprising RGD peptide
- 2810/50 . . Vectors comprising as targeting moiety peptide derived from defined protein
- 2810/55 . . from bacteria
- 2810/60 . . from viruses
- 2810/6009 . . . dsDNA viruses
- 2810/6018 Adenoviridae
- 2810/6027 . . . ssDNA viruses
- 2810/6036 . . . DNA rev transcr viruses
- 2810/6045 . . . RNA rev transcr viruses
- 2810/6054 Retroviridae
- 2810/6063 . . . ds RNA viruses
- 2810/6072 . . . negative strand RNA viruses
- 2810/6081 rhabdoviridae, e.g. VSV
- 2810/609 . . . positive strand RNA viruses
- 2810/65 . . from plants
- 2810/70 . . from fungi
- 2810/75 . . from invertebrates
- 2810/80 . . from vertebrates
- 2810/85 . . . mammalian
- 2810/851 from growth factors; from growth regulators
- 2810/852 from cytokines; from lymphokines; from interferons
- 2810/853 from tumor necrosis factor, TNF
- 2810/854 from hormones
- 2810/855 from receptors; from cell surface antigens; from cell surface determinants
- 2810/856 from integrins
- 2810/857 from blood coagulation or fibrinolysis factors
- 2810/858 from apolipoproteins
- 2810/859 from immunoglobulins
- 2810/90 . . . avian
- 2820/00** **Vectors comprising a special origin of replication system**
- 2820/002 . . inducible or controllable
- 2820/005 . . cell-cycle regulated
- 2820/007 . . tissue or cell-specific
- 2820/10 . . multiple origins of replication
- 2820/55 . . from bacteria
- 2820/60 . . from viruses
- 2820/65 . . from plants
- 2820/70 . . from fungi
- 2820/702 . . yeast
- 2820/704 . . . *S. cerevisiae*
- 2820/706 . . . *S. pombe*
- 2820/708 . . . *C. albicans*
- 2820/75 . . from invertebrates
- 2820/80 . . from vertebrates
- 2820/85 . . mammalian

- 2820/90 . . avian
- 2830/00 Vector systems having a special element relevant for transcription**
- 2830/001 . controllable enhancer/promoter combination
- 2830/002 . . inducible enhancer/promoter combination, e.g. hypoxia, iron, transcription factor
- 2830/003 . . . tet inducible
- 2830/005 . . repressible enhancer/promoter combination, e.g. KRAB
- 2830/006 . . . tet repressible
- 2830/007 . cell cycle specific enhancer/promoter combination
- 2830/008 . cell type or tissue specific enhancer/promoter combination
- 2830/15 . chimeric enhancer/promoter combination
- 2830/20 . transcription of more than one cistron
- 2830/205 . . bidirectional
- 2830/30 . being an enhancer not forming part of the promoter region
- 2830/32 . being an silencer not forming part of the promoter region
- 2830/34 . being a transcription initiation element
- 2830/36 . being a transcription termination element
- 2830/38 . being a stuffer
- 2830/40 . being an insulator
- 2830/42 . being an intron or intervening sequence for splicing and/or stability of RNA
- 2830/46 . elements influencing chromatin structure, e.g. scaffold/matrix attachment region, methylation free island
- 2830/48 . regulating transport or export of RNA, e.g. RRE, PRE, WPRE, CTE
- 2830/50 . regulating RNA stability, not being an intron, e.g. poly A signal
- 2830/52 . encoding ribozyme for self-inactivation
- 2830/55 . from bacteria
- 2830/60 . from viruses
- 2830/65 . from plants
- 2830/70 . from fungi
- 2830/702 . . yeast
- 2830/704 . . . *S. cerevisiae*
- 2830/706 . . . *S. pombe*
- 2830/708 . . . *C. albicans*
- 2830/75 . from invertebrates
- 2830/80 . from vertebrates
- 2830/85 . . mammalian
- 2830/90 . . avian
- 2840/00 Vectors comprising a special translation-regulating system**
- 2840/002 . controllable or inducible
- 2840/005 . cell cycle specific
- 2840/007 . cell or tissue specific
- 2840/10 . regulates levels of translation
- 2840/102 . . inhibiting translation
- 2840/105 . . enhancing translation
- 2840/107 . . inhibiting translational read-through
- 2840/20 . translation of more than one cistron
- 2840/203 . . having an IRES
- 2840/206 . . . having multiple IRES
- 2840/44 . being a specific part of the splice mechanism, e.g. donor, acceptor
- 2840/445 . . for trans-splicing, e.g. polypyrimidine tract, branch point splicing
- 2840/50 . utilisation of non-ATG initiation codon
- NOTE**
- This groups covers artificial modification only, i.e. naturally occurring use of non-ATG start codon is not classified here
- 2840/55 . from bacteria
- 2840/60 . from viruses
- 2840/65 . from plants
- 2840/70 . from fungi
- 2840/702 . . yeast
- 2840/704 . . . *S. cerevisiae*
- 2840/706 . . . *S. pombe*
- 2840/708 . . . *C. albicans*
- 2840/75 . from invertebrates
- 2840/80 . from vertebrates
- 2840/85 . . mammalian
- 2840/90 . . avian
- 2999/00 Further aspects of viruses or vectors not covered by groups [C12N 2710/00](#) - [C12N 2796/00](#) or [C12N 2800/00](#)**
- NOTES**
1. This group is for classification of patent and non-patent literature documents.
 2. When classifying non-patent literature in this group, classification must also be given for the relevant CPC groups, to define the technical area to which they relate.
- 2999/002 . Adverse teaching
- 2999/005 . Biological teaching, e.g. a link between protein and disease, new virus causing pandemic
- 2999/007 . Technological advancements, e.g. new system for producing known virus, cre-lox system for production of transgenic animals